

MERIT MEDICAL SYSTEMS INC
Form PRER14A
April 12, 2018
Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant X

Filed by a Party other than the Registrant O

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

Merit Medical Systems, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Title fee paid:
- Fee paid previously with preliminary materials.
-

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:
-

[Table of Contents](#)

**2018 Notice of
Annual Meeting and
Proxy Statement**

UNDERSTAND.
INNOVATE.
DELIVER.™



Table of Contents

MERIT MEDICAL SYSTEMS, INC.

1600 West Merit Parkway

South Jordan, UT 84095

April 13, 2018

Dear Shareholders:

It is my pleasure to invite you to the 2018 Annual Meeting of Shareholders (or at any adjournment of the meeting) (the [Annual Meeting](#)) of Merit Medical Systems, Inc. ([Merit](#) or the [Company](#)), which will be held on **Thursday, May 24, 2018, at 3:00 p.m. (local time), at our corporate offices at 1600 West Merit Parkway, South Jordan, Utah 84095**. The attached Notice of Annual Meeting of Shareholders and Proxy Statement will serve as your guide to the business to be conducted at, and provide details regarding admission to, the Annual Meeting.

Chairman,

President, and

Chief Executive Officer

We hope you are pleased with Merit's performance during 2017. We successfully completed the last year of our three-year plan and presented two additional years, which forecast continued growth, gross margin improvement and profitability. During the year we completed multiple acquisitions, including the acquisition of the Argon critical care division and Catheter Connections. We also laid the groundwork for our acquisition of soft tissue core needle biopsy and drainage system product lines from Becton, Dickinson and Company, which we completed in February 2018. We are now actively engaged in pursuing a successful transition of those product lines to our marketing channels and manufacturing facilities. During 2017 we also raised additional capital to provide resources for future growth and opportunity. We look forward to the opportunity to discuss these achievements

with you at the Annual Meeting.

We hope you will participate in the Annual Meeting, either by attending and voting in person or by voting (as soon as practicable) through the other acceptable means described in this Proxy Statement. Your vote is important to all of us at Merit. I look forward to seeing you at the Annual Meeting.

Sincerely,

Table of Contents

GUIDE TO PROXY STATEMENT

1	<u>LETTER TO SHAREHOLDERS FROM CHAIR AND CEO</u>
2	<u>GUIDE TO PROXY STATEMENT</u>
3	<u>NOTICE OF 2018 ANNUAL MEETING OF SHAREHOLDERS</u>
4	<u>PROXY SUMMARY</u>
7	<u>CORPORATE GOVERNANCE AND RELATED MATTERS</u>
7	<u>Proposal 1: Election of Nominee Directors</u>
10	<u>Directors Whose Terms of Office Continue</u>
14	<u>Proposal 2: Increase Maximum Board Size (from 9 to 11)</u>
16	<u>Our Board of Directors</u>
22	<u>Non-Employee Director Compensation</u>
23	<u>Related Person Transactions</u>
25	<u>EXECUTIVE COMPENSATION AND RELATED MATTERS</u>
25	<u>Executive Summary</u>
28	<u>Compensation Discussion and Analysis</u>
37	<u>Proposal 3: Advisory Vote on Executive Compensation</u>
39	<u>Proposal 4: Approve our 2018 Long-Term Incentive Plan</u>
45	<u>EXECUTIVE COMPENSATION TABLES</u>
45	<u>Summary Compensation Table</u>
46	<u>Grants of Plan-Based Awards</u>
47	<u>Outstanding Equity Awards at Year End</u>
47	<u>Option Exercises and Stock Vested</u>
47	<u>Non-Qualified Deferred Compensation</u>
49	<u>Potential Payments Upon Termination or Change in Control</u>
53	<u>CEO Pay Ratio</u>
54	<u>AUDIT MATTERS</u>
54	<u>Audit Committee Report</u>
54	<u>Proposal 5: Ratification of Appointment of Independent</u>
	<u>Registered Public Accounting Firm</u>
56	<u>STOCK OWNERSHIP AND TRADING</u>
56	<u>Principal Holders of Voting Securities</u>
57	<u>Section 16(a) Beneficial Ownership Reporting Compliance</u>
58	<u>OTHER PROXY INFORMATION</u>
58	<u>Information About the Annual Meeting and Voting</u>
62	<u>Other Matters</u>
62	<u>Shareholder Proposals for Annual Meeting 2019</u>
63	<u>Non-GAAP Financial Measures</u>
67	<u>EXHIBITS</u>

Purpose of these materials:

On behalf of our Board of Directors, we are making these materials available to you in connection with our solicitation of proxies for our 2018 Annual Meeting of Shareholders. You are receiving this communication because you hold shares of Merit.

What we need from you:

Please read these materials and submit your vote and proxy by telephone, internet or, if you received your materials by mail, by completing and returning your proxy card or voting instructions. Even if you plan to attend the Annual Meeting, we ask that you vote in advance via one of the above means as soon as practicable.

More information:

This Proxy Statement and the accompanying annual report to shareholders are available online at: www.proxyvote.com. You may also request a paper copy of these materials by writing to our Corporate Secretary (Brian G. Lloyd) at the below address:

**MERIT MEDICAL
EXECUTIVE OFFICES**

**1600 West Merit Parkway
South Jordan, UT 84095**

Table of Contents

NOTICE OF 2018 ANNUAL MEETING OF SHAREHOLDERS

PLEASE CAST YOUR VOTE

RIGHT AWAY

HOW TO VOTE

When

May 24, 2018
3:00 P.M. (local time)

Your vote is important to our future. Even if you plan to attend the Annual Meeting, you can vote in advance using another method below (though holders in street name must instruct your broker or nominee). Internet and Phone voting will close at 11:59 P.M. Eastern Time on May 23, 2018.

Where

Merit Medical Systems, Inc.

1600 West Merit Parkway
South Jordan, Utah 84095

BY INTERNET at

www.proxyvote.com

BY PHONE at

1-800-690-6903

(U.S. and Canada)

BY MAIL (cast your ballot,

sign proxy card and post)

Attend meeting

IN PERSON

Items of Business

	MANAGEMENT PROPOSALS	BOARD S RECOMMENDATION	VOTE REQUIRED / BROKER DISCRETIONARY VOTING ALLOWED?	MORE INFORMATION
1	Elect three directors, each to serve until 2021	FOR	Majority* / No	Page 7
2	Amend Merit's Articles of Incorporation to increase maximum Board size (from 9 to 11)	each nominee FOR	Two-Thirds / No	Page 14
3	Non-binding advisory vote to approve named executive officer compensation (Say on Pay)	FOR	Majority* / No	Page 37
4	Approve our 2018 Long-Term Incentive Plan	FOR	Majority* / No	Page 39
5	Ratify appointment of independent registered public accounting firm (Deloitte & Touche)	FOR	Majority* / Yes	Page 54

* Votes cast in favor of the proposal must exceed the votes cast against the proposal. *Majority vote required for each director nominee.*

We will also conduct such other business as may properly come before the Annual Meeting.

Eligibility to Vote

Shareholders of record at the close of business on March 28, 2018 (the record date) may vote at the Annual Meeting.

Important Meeting Information

Whether you plan to attend the Annual Meeting or not, we urge you to vote your shares as soon as possible. As such, please either sign and return the accompanying card in the postage-paid envelope or instruct us via the Internet or phone as to how you would like your shares voted. This will ensure representation of your shares at the Annual Meeting if you are unable to attend.

In order to attend in person, holders of record of shares of Merit's common stock (**Common Stock**) must provide proof of identification. Individuals who own shares in street name must provide proof of ownership and identification. See Other Proxy Information beginning on page 58 for additional information.

By Order of the Board of Directors,

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

This Proxy Statement and the accompanying
Annual Report are available online at:
www.proxyvote.com.

Brian G. Lloyd
Chief Legal Officer and Corporate Secretary

April 13, 2018

3 **2018 PROXY STATEMENT** | www.merit.com

[Table of Contents](#)

PROXY SUMMARY

This summary highlights information contained elsewhere. Please read this Proxy Statement fully before voting.

Governance Highlights

The Board believes good governance is integral to achieving long-term value and is committed to governance policies and practices that benefit the Company and our shareholders. This belief is manifest in:

- Strong lead independent director
- Majority voting for all directors
- No shareholder rights plan (poison pill) or dual class capitalization structure
- Robust code of ethics
- Board with seasoned leaders and broad mix of skills
- Elimination of tax gross-ups and single-trigger change of control feature for executives
- Responsiveness to shareholder input
- Board oversight of Company strategy
- Prohibition of short-term stock trading, short sales and option trading
- Strong alignment between pay and performance for executive compensation
- Share ownership requirements for directors
- Commitment to corporate responsibility

PROPOSAL 1: ELECTION OF THREE

Board Recommendation

2018 NOMINEES FOR DIRECTOR (SEE PAGE 7)

Vote FOR each nominee

You are asked to vote on the election of three nominees to serve on the Board of Directors of Merit (the [Board](#)) until 2021.

The following table provides summary information about each director nominee (first three), as well as each director whose term expires in later years:

NAME, PRIMARY OCCUPATION	AGE	DIRECTOR		TERM		BOARD COMMITTEES		
		SINCE	EXPIRES	INDEPENDENT	A	C	N&CG	
A. SCOTT ANDERSON	71	2011		Yes		•	•	

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

<i>President & CEO of Zions Bank</i> FRED P. LAMPROPOULOS							
<i>Chair, President & CEO of Merit</i> FRANKLIN J. MILLER, M.D.	68	1987		No			
<i>Retired Professor of Radiology</i> NOLAN E. KARRAS	77	2005		Yes	•	•	
<i>Chair & CEO of The Karras Company</i> KENT W. STANGER	73	2011	2020	Yes	•		
<i>Real Estate Investor, Retired CFO of Merit</i> DAVID M. LIU, M.D.	63	1987	2020	No			•
<i>Interventional Radiologist</i> F. ANN MILLNER, ED.D	44	2016	2020	Yes			•
<i>Regents Professor HAS at Weber State Univ.</i> MICHAEL E. STILLABOWER, M.D.	66	2015	2019	Yes			•
<i>Cardiologist</i> THOMAS J. GUNDERSON	74	1996	2019	Yes		•	•
<i>Retired Medtech Analyst at Piper Jaffray</i> •: Committee Chair	67	2017	2019	Yes	•		
A: Audit Committee							
•: Committee Member							
C: Compensation Committee							
							N&CG: Nominating and Corporate Governance Committee

2018 PROXY STATEMENT | www.merit.com 4

Table of Contents

PROPOSAL 2: AMENDMENT TO INCREASE MAXIMUM

Board Recommendation

NUMBER OF DIRECTORS (SEE PAGE 14)

Vote FOR this amendment

The Nominating and Corporate Governance Committee (the [Governance Committee](#)) has recommended, and the Board has approved, an increase in the maximum number of directors of the Company, to allow the Governance Committee to seek and add additional directors with diverse experience, background or skills that the Board believes will

provide added perspective and value to the Company and its shareholders. The amendment requires approval of the holders of at least two-thirds of the outstanding shares of Common Stock. If approved, the amendment will be reflected in our articles and bylaws.

The Board has not selected any nominees to fill vacancies on the Board which might be created if the amendment is approved. If the amendment is approved and our Board votes to increase the size of the Board, any vacancies which would be created by such increase would be filled by the Board; however, any directors appointed by the Board to fill such vacancies would serve only until the next election of directors by our shareholders.

SELECT PERFORMANCE HIGHLIGHTS IN 2017

Access and Review

The Company had another successful year in 2017. Highlights of our business and compensation are included below:

For more complete information about our 2017 financial performance, see our Annual Report on Form 10-K

SELECTED 2017 HIGHLIGHTS

- Successful completion of three-year plan to accelerate growth and improve profitability and extension of the plan for two additional years
- Achievement of net sales, non-GAAP gross margin, and GAAP and non-GAAP earnings per share financial performance objectives

- Completed multiple significant acquisition transactions, including the critical care division of Argon Medical Devices, Inc. and Catheter Connections, Inc., with expanded Merit presence in Asia Pacific
- Completed transition to limited direct sales model in Japan, designed to increase Merit responsiveness and profitability
- Cumulative total return on our Common Stock from December 31, 2012 to December 31, 2017 of 211% (1)

(1) See Item 5 of our Annual Report on Form 10-K filed on March 1, 2018. Past results are not necessarily an indicator of future results.

PROPOSAL 3: ADVISORY VOTE ON EXECUTIVE

Board Recommendation

COMPENSATION (SAY-ON-PAY)

Vote FOR this proposal

(SEE PAGE 37)

Consistent with our strong interest in shareholder engagement and our pay-for-performance approach, the Compensation Committee of our Board (the Compensation Committee) has continued to examine our executive compensation program to encourage alignment between the interests of our executives and shareholders. In particular, following abnormally low support for our executive compensation program at our 2017 annual meeting, the Compensation Committee undertook extensive conversations with our Board, management and shareholders and reviewed corporate governance practices at other companies. Based on these discussions and review, we amended our employment agreements with each Named Executive Officer (NEO) to ensure that such agreements do not include a parachute payment tax gross-up provision or allow any of the NEOs to qualify for

change-in-control benefits solely upon a change in control. We believe the amendments are responsive to the concerns expressed by our shareholders and consistent with good corporate governance practices.

We ask that our shareholders approve, on an advisory basis, the compensation of our NEOs.

For additional information, see Compensation Discussion and Analysis in this Proxy Statement.

5 **2018 PROXY STATEMENT** |
www.merit.com

Table of Contents

PROPOSAL 4: APPROVE THE COMPANY'S 2018 LONG-TERM INCENTIVE PLAN (SEE PAGE 39)

Board Recommendation

Vote **FOR** this amendment

The Merit Medical Systems, Inc. 2006 Long-Term Incentive Plan, as amended (the [2006 Incentive Plan](#)), has been an important tool to attract and retain quality executives, directors, employees, and consultants. As of March 31, 2018, only 2,290 shares remained available for future awards under the 2006 Incentive Plan. This amount is not sufficient for future anticipated awards, and our Governance Committee and Board believe we should maintain an equity incentive plan with sufficient capacity to make

awards which will align the interests of our employees and directors with our shareholders.

We therefore ask that our shareholders approve a new 2018 Long-Term Incentive Plan (the 2018 Incentive Plan) in order to permit us to continue to grant equity-based awards and attract and retain quality executives, directors, employees and consultants.

PROPOSAL 5: RATIFY APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (SEE PAGE 54)

Board Recommendation

Vote **FOR** ratification

We have engaged Deloitte & Touche LLP ([Deloitte](#)) as our independent registered public accountants since 1988, shortly after the Company was founded. The Board believes Deloitte continues to be the right accounting firm for our business and, consequently, has engaged Deloitte to audit our financial

statements for the year ending December 31, 2018, subject to ratification by our shareholders.

The Board asks that our shareholders ratify this appointment.

Below is summary information about Deloitte's fees for 2017 and 2016.

	2017 (\$)	2016 (\$)
Audit Fees	993,286	835,920
Audit-Related Fees	81,083	27,527
Tax Fees	313,513	326,041
All Other Fees	151,443	131,000
Total	1,539,325	1,320,488

HOW TO RECEIVE A PAPER OR E-MAIL COPY OF THESE PROXY MATERIALS

If you want to receive a paper or e-mail copy of these documents, you must request one. There is **no** charge for requesting a copy. Please choose one of the following methods to make your request:

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

- (1) BY INTERNET: www.proxyvote.com
- (2) BY TELEPHONE: 1-800-579-1639
- (3) BY E-MAIL: sendmaterial@proxyvote.com

If you are requesting material by e-mail, please send a blank e-mail with the 12-digit control number printed on the ballot enclosed with this Proxy Statement in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will **not** be forwarded to your investment advisor. Please make the request as instructed above on or before May 10, 2018 to facilitate timely delivery.

To view these proxy materials online, please have the 12-digit control number printed on the ballot enclosed with this proxy statement and visit www.proxyvote.com.

2018 PROXY STATEMENT | www.merit.com 6

[Table of Contents](#)

CORPORATE GOVERNANCE AND RELATED MATTERS

PROPOSAL NO. 1: ELECTION OF NOMINEE DIRECTORS

At the Annual Meeting, three directors will be elected to serve until our 2021 annual meeting of shareholders and until their successors are duly elected and qualified. If any of the below nominees become unavailable to serve, proxies solicited by this Proxy Statement will be voted for other persons designated by the Board in their stead.

Classification of Board of Directors

Our Articles provide for a classified, or staggered, Board. Our directors are divided into three classes, with directors in each class serving a three-year term. Approximately one-third of our directors' terms expire at each annual shareholders meeting. Based upon the existing classification of the Board, the terms of A. Scott Anderson, Fred P. Lampropoulos, and Franklin J. Miller, M.D., are scheduled to expire in connection with the Annual Meeting.

Board Recommendation

The Board unanimously recommends a vote FOR each of the below director nominees

Nominees for Election as Directors

Our Board and Governance Committee believe that each of the following nominees possesses the experience and qualifications that directors of the Company should possess, as described in detail below, and that the experience and qualifications of each nominee complement the experience and qualifications of the other nominees.

The experience and qualifications of each nominee, including information regarding the specific experience, qualifications, attributes and skills that led the Board and the Governance Committee to conclude that he or she should be nominated to serve as a director of the Company, in light of our business and structure, are set forth below:

	<p>A. SCOTT ANDERSON</p> <p>Independent Director</p> <p>Age: 71</p>	<p>Director Since: November 2011</p> <p>Committees: Compensation (Chair); Governance</p> <p>Other Public Boards: None</p> <p>Education: B.A. (philosophy, economics), Columbia University; M.S. (economics, international studies), Johns Hopkins University</p>
--	--	--

Career Highlights

- President and CEO of Zions First National Bank (commercial bank based in the intermountain U.S.), 1998 to present
- Member of Board of Trustees of Intermountain Healthcare (integrated healthcare system in Utah and Idaho), 2005 to present (Chair, 2012 to present)
- Director of the Federal Reserve Bank of San Francisco (Salt Lake City Branch), 2003 to 2008

Qualifications of Particular Relevance to Merit

Mr. Anderson contributes to the Board's deliberations more than 40 years of experience in the banking and financial services industries. The Board believes Mr. Anderson provides insight regarding national and international financial and credit markets, as well as lending practices, which are valuable as we continue to implement our growth strategy. Mr. Anderson also contributes extensive business and corporate governance experience to the strategic planning and operational discussions of the Board.

7 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

	<p>FRED P. LAMPROPOULOS</p> <p>Chair, President, CEO</p> <p>Age: 68</p>	<p><u>Director Since:</u> July 1987</p> <p><u>Committees:</u> None</p> <p><u>Other Public Boards:</u> None</p>
--	--	--

Career Highlights

- Chair of the Board, CEO, and President of the Company since its formation in July 1987
- Chair of the Board and President of Utah Medical Products, Inc. (medical device manufacturer), 1983 to 1987
- Filed more than 200 domestic and international patents and applications on medical devices
- Serves on several community and advisory boards
- Recipient of numerous awards, including 2003 Utah Governor's Medal for Science and Technology

Qualifications of Particular Relevance to Merit

The Board believes the Company benefits immensely from Mr. Lampropoulos' experience as founder, President and Chief Executive Officer of the Company. He plays an essential role in communicating the expectations, advice, concerns and encouragement of the Board to our employees. Mr. Lampropoulos has a deep knowledge and understanding of the Company, as well as the industry and markets in which our products compete. Mr. Lampropoulos also performs an essential function as the Chair of the Board, providing decisive leadership and direction to the activities and deliberations of the Board. The Board also believes Mr. Lampropoulos' leadership, drive and determination are significant factors in our growth and development and continue to be tremendous assets to the Company and its shareholders.

	<p>FRANKLIN J. MILLER, M.D.</p> <p>Independent Director</p>	<p><u>Director Since:</u> May 2005</p> <p><u>Committees:</u> Audit, Compensation</p> <p><u>Other Public Boards:</u> None</p> <p><u>Education:</u> B.S. (pre-med), Pennsylvania State University; M.D., Temple University Medical School; Resident and fellowship, Johns Hopkins University</p>
--	---	--

	Age: 77	
--	---------	--

Career Highlights

- Consultant to the Company, assisting in product testing and development, 1997 to 2005
- Professor of Radiology and Surgery at the University of Utah Department of Radiology, 1976 to 2005 (Director of Interventional Radiology, 1976 to 2001)
- Clinical Professor of Radiology at the University of California, San Diego (began the Hereditary Hemorrhagic Telangiectasia Clinic, one of only eight such clinics in the United States), 2002 to 2011
- Served on advisory boards to several medical device companies and member of editorial and review boards for numerous medical journals

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

Qualifications of Particular Relevance to Merit

Dr. Miller contributes a valuable set of skills, training and experience to the Board's deliberations. During his service as a director, Dr. Miller has provided significant advice regarding our product development strategy and plays a significant role in our evaluation of acquisition and other growth opportunities. Based, in part, on his extensive medical training and his experience with various medical devices, Dr. Miller provides the Board valuable insight regarding the needs and preferences of the medical professionals who use and purchase our products.

Retirement Policy

Our Corporate Governance Guidelines require that, upon reaching 75 years of age, each director must submit to the Board a letter of resignation to be effective at the next annual meeting of shareholders. The Board will generally accept all such resignations unless the Governance Committee or the Board determines to nominate the director for another term. Upon reaching 75 years of age, Dr. Miller tendered to the Board such a letter of resignation, which was considered by our Governance Committee and the Board. Following such consideration, the Board declined to accept Dr. Miller's resignation. The Governance Committee and the Board also considered our director retirement policy when nominating Dr. Miller to serve for another term. The Governance Committee has determined that, despite being beyond the retirement age set forth in our Corporate Governance Guidelines, Dr. Miller continues to provide significant contributions to our Board and the Company and his unique perspective and extensive skills and experience continue to provide a valuable asset to the Board and the Company.

Table of Contents

DIRECTORS WHOSE

TERMS OF OFFICE CONTINUE

In its regular discussions regarding Board composition, the Governance Committee works with the Board to determine the appropriate mix of professional experience, areas of expertise, educational background and other qualifications that are particularly desirable for our directors to possess in light of our current and future business strategies.

The Board believes that its current members have the right combination of experience and qualifications to continue to lead the Company to success. Information regarding the specific experience, qualifications, attributes and skills that led the Board and the Governance Committee to conclude that each continuing director should serve on the Board are set forth below:

NOLAN E. KARRAS

Lead Independent Director (since May 2017)

Governance Highlights

The Board believes good governance is integral to achieving long-term shareholder value and is committed to governance policies and practices that benefit the Company and its shareholders. This belief is manifest in:

- Strong lead independent director
- Majority voting for all directors
- No shareholder rights plan (poison pill)
- No dual class capitalization structure
- Annual say on pay advisory votes
- Robust code of ethics
- Share ownership requirements for directors
- Board oversight of Company strategy
- Prohibition of short-term stock trading, short sales and option trading
- Responsiveness to shareholder input
- Commitment to corporate responsibility
- Strong alignment between pay and performance for executive compensation

Director Since: November 2011

Committees: Audit (Chair)

Other Public Boards: PacifiCorp, Scottish Power

Age: 73

Education: B.A., Weber State University; M.B.A., University of Utah; Certified Public Accountant

Term Expires: 2020

Career Highlights

- Chair and CEO of The Karras Company, Inc. (investment advisory firm), 1997 to present
- Chair of Utah Governor's Education Excellence Commission, 2015 to present
- Member of Board of Trustees of Weber State University (chair of audit committee), 2013 to present
- Community Board of Directors of University of Utah Hospitals and Clinics (chair of finance committee), 2009 to 2014
- CEO of Western Hay Company, Inc. (agricultural products company in Utah), 1995 to 2012 (remains board member)
- Board of Directors of Beneficial Life Insurance Company (privately-held life insurance company headquartered in Utah) (chair of finance committee and member of executive committee), 1996 to 2009,
- Member of the Utah State Board of Regents, 2001 to 2013 (chair, 2002 to 2006)
- Former director and member of audit and compensation committees of boards of directors of PacifiCorp (a public utility operating in the northwestern United States) and Scottish Power (multinational energy company)
- Several positions in public service, including ten years as Speaker of the House and House Majority Leader of the Utah House of Representatives

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

Qualifications of Particular Relevance to Merit

Mr. Karras' experience and skills qualify him to work constructively with our management and directors, especially in connection with our pursuit of growth and expansion opportunities. The Board believes Mr. Karras' financial acumen and experience in corporate governance are valuable to its deliberations and strategic planning and in his service as Chair of the Audit Committee. Mr. Karras also has a keen awareness of the social, political and economic environment in which the Company operates.

	<p>KENT W. STANGER</p> <p>Director</p> <p>Age: 63</p>	<p>Director Since: September 1987</p> <p>Committees: Governance</p> <p>Other Public Boards: None</p> <p>Education: B.A. (accounting), Weber State University; former Certified Public Accountant</p> <p>Term Expires: 2020</p>
--	--	---

Career Highlights

- Member of Board of Directors and Executive Committee of Utah Taxpayers Association, 2012 to 2016
- Chief Financial Officer, Secretary and Treasurer of the Company, 1987 to 2015
- Controller of Utah Medical Products, Inc. (medical device manufacturer), 1985 to 1987
- Corporate Controller for Laser Corporation, American Laser and Modulaire Industries, Inc., 1982 to 1985
- Hansen, Barnett and Maxwell (former Utah accounting firm that merged with Eide Bailly LLP in 2013) as practicing certified public accountant, 1979 to 1982

Qualifications of Particular Relevance to Merit

Mr. Stanger was a founder of the Company and, through more than 25 years of service as the principal financial manager of the Company, developed a broad understanding of our business and operations, as well as the industry and markets in which the

Company competes. The Board values Mr. Stanger's accounting and financial management skills and benefits greatly from his extensive knowledge of our history, achievements, competitive position and strategic objectives.

Appointment to Governance Committee

Shares of our Common Stock are listed on The NASDAQ Global Select Market (**NASDAQ**). NASDAQ does not require that companies maintain a separate nominations committee, but does require that director nominees be selected either by a vote of (a) all independent directors of the Board (in which vote, non-independent directors may not participate) or (b) of a nominations committee composed of independent directors (within the meaning of NASDAQ Rule 5605(a)(2)). As Mr. Stanger was employed by the Company until November 2015, he does not meet that definition of independent director. However, NASDAQ Rule 5605(e)(3) provides an exception to this rule that allows one director who does not otherwise meet the definition of independent director and who is not then an executive officer of the company to be appointed to the company's nominations committee if (a) the nominations committee is comprised of at least three members and (b) under exceptional and limited circumstances, the board of directors determines that such individual's membership on the committee is required in the best interests of the company and its shareholders.

Having considered all relevant factors, including Mr. Stanger's significant background with the Company, his substantial industry experience and his contributions in orienting and providing onboarding training for new directors, the Board concluded in 2017 that appointing Mr. Stanger to the Governance Committee was in the best interests of the Company and its shareholders and did not believe that Mr. Stanger's former employment by, and compensation received as an executive officer of, the Company would interfere with his exercise of independent judgment in carrying out the responsibilities of a member of the Governance Committee.

Table of Contents

	<p>DAVID M. LIU, M.D.</p> <p>Independent Director</p> <p>Age: 44</p>	<p>Director Since: July 2016</p> <p>Committees: Governance</p> <p>Other Public Boards: None</p> <p>Education: M.D., University of Toronto; Radiology residency at University of British Columbia; Interventional radiology fellowship at Northwestern Memorial Hospital</p> <p>Term Expires: 2020</p>
--	---	--

Career Highlights

- Interventional radiologist (certified in the U.S. and Canada), practicing at the Vancouver General Hospital, University of British Columbia Hospital, and BC Cancer Agency (with cross appointment in surgery department), 2008 to present
- Clinical Associate Professor of Radiology at the University of British Columbia, 2008 to present
- Medical Director at Eva Vein Care (team of physicians specializing in diagnostic assessment, endovascular therapy and interventional radiology), 2012 to present
- Co-founder and co-chair of the international liver cancer symposium, SHOW
- Credited with 7 book chapters, over 60 publications, and 100 invited lectures around the world
- Inducted Fellow of the Society of Interventional Radiology

Qualifications of Particular Relevance to Merit

In addition to bench side and clinical research in the fields of novel embolic platforms, ablative technologies and cancer-related thromboembolic disease, Dr. Liu maintains an interventional oncology practice incorporating multiple aspects of embolization, ablation, venous access, and palliative therapy in organ systems. Fluent in mandarin, Dr. Liu is an active member of the interventional radiology community and has served as an advisor on multiple global advisory boards and technology development committees for various scientific and commercial organizations. The Board believes Dr. Liu's extensive industry experience, scientific credentials and active clinical practice provide him with vital insights into the trends, risks and opportunities in many of our core interests. Dr. Liu also contributes valuable clinical and industry perspective to the Board's analysis of prospective acquisitions, product development and other strategic decisions.

	<p>F. ANN MILLNER, Ed.D</p> <p>Independent Director</p> <p>Age: 66</p>	<p>Director Since: July 2015</p> <p>Committees: Governance (chair)</p> <p>Other Public Boards: None</p> <p>Education: B.S. (education), University of Tennessee; M.S. (allied health education and management), Southwest Texas State University;</p> <p>Ed.D (education administration), Brigham Young University; Completed medical technology program, Vanderbilt University</p> <p>Term Expires: 2019</p>
--	---	--

Career Highlights

- Regents Professor and Professor of Health Administrative Services at Weber State University, 2013 to present
- Member of the Utah State Senate (member of multiple committees and subcommittees), 2015 to present
- Member of Utah Governor’s Task Force on Educational Excellence, 2015 to present
- Member of Board of Trustees of Intermountain Healthcare (integrated healthcare system in Utah and Idaho), 2005 to present (serving as Vice Chair, 2017 to present)
- President of Weber State University, 2002 to 2012 (first female president of a Utah state university)
- Vice President of University Relations at Weber State University, 1993 to 2002
- Associate Dean of Continuing Education and Assistant Vice President of Community Partnerships at Weber State University, 1985 to 1993

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

Qualifications of Particular Relevance to Merit

The Board believes Dr. Millner's qualifications to serve as a director of the Company include her executive leadership skills and her experience in the areas of organizational administration, operations and financial management, and business strategy. During her service as the Chair of our Governance Committee, Dr. Millner has played a significant role in the development of our corporate governance practices and engagement with our shareholders.

	<p>MICHAEL E. STILLABOWER, M.D.</p> <p>Independent Director</p> <p>Age: 74</p>	<p>Director Since: March 1996</p> <p>Committees: Compensation; Governance</p> <p>Other Public Boards: None</p> <p>Education: B.S. (electrical engineering, Purdue University; M.D., Sidney Kimmel Medical College; Residency, Wilmington Medical Center; Fellowship, Washington D.C. VA Medical Center</p> <p>Term Expires: 2019</p>
--	---	---

Career Highlights

- Director of Cardiovascular Clinical Trials at Christiana Care Health Systems, 1999 to 2014
- Chief of Cardiology at Medical Center of Delaware, 1988 to 1999 (director of coronary care unit, 1984 to 1988)
- Clinical Associate Professor of Medicine, Sidney Kimmel Medical College, 1995 to present
- Elected Fellow of the American College of Cardiology and a member of other professional associations and is actively engaged in cardiology research, instruction and publication of related papers and abstracts

Qualifications of Particular Relevance to Merit

Dr. Stillabower's service reflects the Board's recognition of his expertise in the medical profession, his valuable role in developing and evaluating existing and proposed Company products and his understanding of the medical community and the markets for our products. Dr. Stillabower contributes more than 30 years of specialized training and experience in cardiology and related fields to the Board, and has actively participated in the development and commercialization of many of our products. He has used our products in cardiac procedures and provides valuable insights from a practitioner's viewpoint.

	<p>THOMAS J. GUNDERSON</p> <p>Independent Director</p> <p>Age: 67</p>	<p>Director Since: May 2017</p> <p>Committees: Audit</p> <p>Other Public Boards: None</p> <p>Education: B.A. (biology focus), Carleton College; M.S. (cell biology), University of Minnesota; M.B.A., University of St. Thomas</p> <p>Term Expires: 2019</p>
--	--	---

Career Highlights

- Chair of the Board of Directors at the Minneapolis Heart Institute Foundation, 2015 to present
- Executive in Residence at the University of Minnesota's Medical Industry Leadership Institute, 2016 to present
- Member of American Heart Association Science and Technology Accelerator Committee, 2015 to 2017

Table of Contents

- Managing director and senior research analyst at Piper Jaffray (focus on medical technology companies), 1992 to 2016
- Project Director at American Medical Systems (private medical device company acquired by Pfizer in 1983), 1979 to 1992
- Recognized by several industry publications, including the Wall Street Journal, Institutional Investor, First Call, Thomson Reuters, and Medical Device and Diagnostic Industry (e.g., in 1996 and 2000, he was named an All-Star Analyst for medical stocks by the Wall Street Journal and in 2014, Thomson-Reuters named him Top Stock Picker in the medical technology sector)

Qualifications of Particular Relevance to Merit

Mr. Gunderson provides the Board with more than 25 years of substantive experience in the medical device industry, with a seasoned perspective on the challenges, trends and opportunities of publicly-traded medical device manufacturers, as well as a keen understanding of the Company's competitive position within its industry. Mr. Gunderson also contributes a strong background in financial and economic analysis and valuable insights regarding business development and acquisition opportunities.

PROPOSAL NO. 2:

**APPROVE AMENDMENT TO INCREASE
MAXIMUM BOARD SIZE (FROM 9 TO
11)**

Board Recommendation

**The Board unanimously recommends a vote
FOR this proposal**

The Board has, subject only to receiving shareholder approval, voted to adopt the Second Amended and Restated Articles of Incorporation (the [Revised Articles](#)), which has been amended to increase the maximum number of directors from nine to eleven. If the holders of at least two-thirds of the outstanding shares of Common Stock approve the Revised Articles, we intend to (a) promptly file the Revised Articles with the Division of Corporations of the State of Utah (at which time, they will become effective) and (b) amend our Second Amended and Restated Bylaws (the [Bylaws](#)) to reflect the same change. The amendment to our Bylaws does not require shareholder approval.

Our current Amended and Restated Articles of Incorporation and Bylaws provide that the number of directors of the Company shall be not less than three nor more than nine (as may be determined and established from time to time by the Board). As of the date of this Proxy Statement, the Board has fixed the number of directors at nine.

Any vacancy occurring in the Board, including any vacancy created by an increase in the number of directors, may be filled by the vote of a majority of the directors then in office.

The Board believes that the size of the Board should be increased to allow the Governance Committee to seek and add additional directors with diverse experience, backgrounds or skills that the Board believes will provide added perspective and value to the Company and its shareholders. The Board has not selected any nominees to fill vacancies on the Board which might be created if the Revised Articles are approved. If the Revised Articles are approved and our Board votes to increase the size of the Board, any vacancies which would be created by such increase would be filled by the Board; however, any directors appointed by the Board to fill such vacancies would serve only until the next election of directors by our shareholders.

The Revised Articles will also remove an obsolete provision related to the minimum paid-in-capital of the Company (Article V of the current Amended and Restated Articles of Incorporation), which no longer applies. The remaining articles (and any applicable cross-references) will be renumbered accordingly.

The text of Article V in the Revised Articles is set forth below (with changes marked in blue for ease of review). The full text of the Revised Articles is included as [Exhibit 1](#) to this Proxy Statement.

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

ARTICLE VI

DIRECTORS

The board of directors shall consist of such number of members, which number shall not be less than three and not more than ~~nine~~ **eleven** as may be determined and established from time to time by the board of directors and shall be divided into three classes, as nearly equal in size as possible. No increase in the maximum number of members shall be made except upon the affirmative vote of not less than two-thirds of the outstanding capital stock of the corporation entitled to vote thereon. ~~The initial terms of directors first elected or reelected by the shareholders after the adoption of this amendment and revision of the Articles of Incorporation shall be for the following terms of office:~~

~~Class A Directors—One Year~~

~~Class B Directors—Two Years~~

~~Class C Directors—Three Years~~

~~Upon the expiration of the initial term specified for each class of directors, their successors~~

Directors shall be elected for three-year terms or until such time as their successors shall be elected and qualified, with one class of directors to be elected each year.

Vacancies on the board of directors, whether the result of removal (with or without cause), death, resignation or otherwise, shall be filled by majority vote of the remaining members of the board of directors, regardless of whether such remaining members constitute a quorum.

The corporation shall nominate persons to serve as members of the board of directors upon the expiration of the term of each class of directors, which nominations shall be submitted to the shareholders at the annual meeting of shareholders for approval. Any nominations for election to the board of directors shall be received, with respect to any annual meeting of shareholders, not later than the date specified by the board of directors for submission of such nominations. Failure to submit timely nominations shall prevent consideration of the nominations at such annual shareholders meetings.

Directors of the corporation may be removed for cause only upon the affirmative vote of the holders of a majority of the outstanding capital stock entitled to vote thereon. A director may be removed for cause only after a finding that (i) the director engaged in fraudulent or dishonest conduct or gross abuse of authority or discretion, with respect to the corporation and (ii) removal is in the best interests of the corporation. Directors of the corporation may be removed for any reason other than cause only upon the affirmative vote of the holders of not less than two-thirds of the outstanding capital stock of the corporation entitled to vote thereon.

Table of Contents

OUR BOARD OF DIRECTORS

Our business affairs are managed subject to the oversight of the Board, which represents and is accountable to the shareholders of the Company. The Board advises and oversees management, which is responsible for the day-to-day operations of the Company. The primary mission of the Board is to represent and protect the interests of our shareholders. As a result, the basic responsibility of our directors is

to act in good faith and with due care so as to exercise their business judgment on an informed basis in what they reasonably and honestly believe to be in the best interests of the Company and its shareholders. The Board reviews and assesses our strategic, competitive and financial performance.

Board Leadership Structure

Chair of the Board

The Chair of the Board provides leadership to the Board and works with it to define its structure, agenda and activities in order to fulfill its responsibilities. The Chair works with senior management to help ensure that matters for which management is responsible are appropriately reported to the Board.

shareholders, and his proven leadership skills, the Board believes Mr. Lampropoulos' continued service in both capacities serves the best interests of our shareholders. Further, the Board believes Mr. Lampropoulos' fulfillment of both responsibilities encourages accountability and effective decision-making and provides strong leadership for employees and other stakeholders.

Fred P. Lampropoulos currently serves as the Chair of the Board and CEO of the Company. The Board and Governance Committee believe that the traditional practice of combining the roles of chair of the board and chief executive officer currently provides the preferred form of leadership for the Company. Given Mr. Lampropoulos' vast experience since founding the Company in 1987, his role as an inventor and his involvement in filing more than 200 patents and pending applications, the respect which he has earned from our employees, business partners and

Lead Independent Director

In May 2017, the independent directors of the Company selected Mr. Karras to serve as the Lead Independent Director. The position of Lead Independent Director comes with clearly delineated and comprehensive duties, as set out in the Board's Corporate Governance Guidelines, adopted on February 12, 2015 (as amended from time to time, the [Governance Guidelines](#)).

These duties include:

<p>BOARD MEETINGS AND EXECUTIVE SESSIONS</p>	<ul style="list-style-type: none"> • Authority to call meetings of the independent directors • Presides at all meetings of the Board at which the Chair is not present, including executive sessions of the independent directors
---	---

COMMUNICATING WITH MANAGEMENT	<ul style="list-style-type: none"> Serves as principal liaison between the Chair/CEO and the independent directors
AGENDAS	<ul style="list-style-type: none"> Approves meeting agendas for the Board and information sent to the Board by the Chair/CEO, including supporting materials
MEETING SCHEDULES	<ul style="list-style-type: none"> Approves meeting schedules for the Board to assure that there is sufficient time for discussion of all agenda items
COMMUNICATING WITH SHAREHOLDERS	<ul style="list-style-type: none"> Ensures availability for consultation and direct communication with major shareholders of the Company upon reasonable request

Our independent directors meet in executive session without the CEO/Chair present regularly, generally at least quarterly.

During these sessions, independent directors discuss topics such as executive (including the CEO) succession planning, corporate governance, business strategy and Board responsibilities.

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

Composition and Selection of Board Members

The Governance Committee is responsible for reviewing annually with the Board the desired skills and characteristics of directors, as well as the composition of the Board as a whole. Directors should be individuals who have succeeded in their particular field and who demonstrate integrity, reliability, knowledge of corporate affairs, and an ability to work well together. Directors should have:

- demonstrated management ability at senior levels in successful organizations;
- current or recent employment in positions of significant responsibility and decision-making;
- expertise in the medical device industry, medical profession or related areas of training; or
- current and prior experience related to anticipated Board and committee responsibilities in other areas of importance to the Company.

The Governance Committee reviews the skills and characteristics required of directors in the context of the current composition of the Board. There is currently no set of specific minimum qualifications that must be met by a nominee recommended by the Governance Committee, as different factors may assume greater or lesser significance at particular times and the needs of the Board may vary in light of its composition and the Governance Committee's perceptions about future issues and needs. Additionally, in considering the composition of the Board and identifying nominees, the Governance Committee does not have a formal policy regarding the

- capacity to evaluate strategy and reach sound conclusions;
- availability of time to devote to the Board; and
- awareness of relevant social, political, and economic trends affecting the Company.

The Governance Committee utilizes a variety of methods for identifying and evaluating director nominees. The Governance Committee assesses the appropriate size of the Board, and whether any vacancies on the Board are expected due to retirement or otherwise. In the event that vacancies are anticipated, or otherwise arise, the Governance Committee considers various potential candidates for director. Candidates may come to the attention of the Governance Committee through various means, including recommendations from current directors, shareholders or other individuals. To date, the Governance Committee has not engaged a professional search firm to assist in identifying candidates for service on the Board.

Shareholder Recommendations

The Governance Committee considers properly-submitted director-nominee recommendations from shareholders prior to the issuance of the proxy statement for the next annual meeting of shareholders. Materials provided by a shareholder in connection with such a recommendation are forwarded to the Governance Committee. In evaluating those recommendations, the Governance Committee seeks to achieve a balance of knowledge, experience and capability on the Board and to address the membership criteria described below.

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

consideration of gender, race, sexual preference, religion and other traits typically associated with the term diversity.

Any shareholder wishing to recommend a candidate for consideration by the Governance Committee should submit a recommendation in writing indicating the candidate's qualifications and other relevant biographical information and provide confirmation of the candidate's consent to serve as a director.

However, the Governance Committee considers it important that the Board be composed of directors with a diverse range of experience, areas of expertise and skills and considers several factors, including a candidate's:

Interested shareholders should send recommendations to:

- age;
- skills;
- integrity and moral responsibility;
- policy-making experience;
- ability to work constructively with our management and other directors;
- diversity;

Merit Medical Systems, Inc.

Attn: Brian G. Lloyd

1600 West Merit Parkway

South Jordan, Utah 84095

Table of Contents

The table below shows some of the relevant experience of our directors identified by the Governance Committee.

	EXPERIENCE	
--	-------------------	--

DIRECTOR NAME	MEDICAL DEVICE INDUSTRY	MEDICAL PROFESSIONAL	FINANCIAL OR ACCOUNTING	PUBLIC COMPANY	CAPITAL MARKETS	ORGANIZATIONAL AND POLICY MAKING	OWNERSHIP OR INVENTORSHIP
A. SCOTT ANDERSON			•	•	•	•	
THOMAS J. GUNDERSON			•		•		
NOLAN E. KARRAS			•	•	•		
FRED P. LAMPROPOULOS	•			•	•		•
DAVID M. LIU, M.D.	•	•				•	•
FRANKLIN J. MILLER, M.D.	•	•		•		•	•
F. ANN MILLNER, ED.D			•			•	
MICHAEL STILLABOWER, M.D.	•	•					
KENT W. STANGER	•		•	•	•	•	•

Independence Determinations for Directors

Under our Governance Guidelines, a significant majority of our Board members should be independent directors who meet the director independence guidelines set forth in the NASDAQ Marketplace Rules, on which shares of the Common Stock are currently quoted. Among other things, each independent director should be free of significant business connections with competitors, suppliers, or customers of the Company.

In 2017, the Governance Committee undertook its annual review of director and nominee

independence and recommended that the Board determine that Mr. Anderson, Mr. Gunderson, Mr. Karras, Dr. Liu, Dr. Miller, Dr. Millner and Dr. Stillabower each be designated as an independent director. Mr. Lampropoulos is not independent because of his employment as President and CEO of the Company. Mr. Stanger may not be considered to be independent for some purposes because of his employment as Chief Financial Officer of the Company until 2016.

Board Meetings and Committees

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

In 2017, the Board met 12 times. Directors are expected to attend regular Board meetings, Board committee meetings and annual shareholder meetings. The independent directors met in executive session four times during 2017.

As further described below, the Board has a standing Audit Committee, Compensation Committee, and Governance Committee. The Company believes each of the directors serving on the Audit, Compensation, and Governance Committees (other than Mr. Stanger's service on the Governance Committee) is an independent director for

All directors attended at least 75% of the total number of meetings of the Board and of any committee on which he or she served.

purposes of the Marketplace Rules of NASDAQ and that each of the directors serving on the Compensation Committee is a non-employee director for purposes of Rule 16b-3 of the Securities Exchange Act of 1934, as amended ([the Exchange Act](#)).

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

Audit Committee

The Audit Committee meets to review and discuss our accounting practices and procedures and quarterly and annual financial statements with our management and independent public accountants. The Audit Committee assists the Board in fulfilling its responsibility for oversight of the quality and integrity of our accounting, auditing and reporting practices.

The Audit Committee's primary duties include:

- reviewing the scope and adequacy of internal accounting and financial controls;
- reviewing the independence of our independent registered public accounting firm;
- approving the scope and results of the audit activities of our independent accountants;
- approving fees of, and non-audit related services by, our independent accountants;
- reviewing our compliance and enterprise risk management programs;

AUDIT COMMITTEE MEMBERS

- Nolan E. Karras (Chair)
- Franklin J. Miller
- Thomas J. Gunderson

FINANCIAL EXPERTS ON AUDIT COMMITTEE

The Board has determined that Mr. Karras and Mr. Gunderson are audit committee financial experts, as defined in Item 407(d) of Regulation S-K under the Exchange Act.

- reviewing the objectivity and effectiveness of our internal audit function;
- reviewing our financial reporting activities and the accounting standards and principles followed;
and
- reviewing and approving related person transactions.

The Audit Committee met five times during 2017.

Compensation Committee

The Compensation Committee is responsible for overseeing, reviewing and approving executive compensation and benefit programs of the Company. Additional information regarding the functions, procedures and authority of the Compensation Committee is provided in the Compensation Discussion and Analysis beginning on page 28 below. The Compensation Committee Report appears on page 37 below.

The Compensation Committee met three times formally during 2017, although members of the Compensation Committee also met informally and discussed compensation issues at other times throughout the year.

Nominating and Corporate Governance Committee

The Governance Committee is responsible for nomination of our directors and oversight of our corporate governance activities. As discussed earlier, the Governance Committee selects, evaluates and recommends to the full Board qualified candidates for election to the Board. The Governance Committee also provides oversight of our corporate governance practices, including the practices set forth in our Governance Guidelines.

COMPENSATION COMMITTEE MEMBERS

- A. Scott Anderson (Chair)
- Franklin J. Miller, M.D.
- Michael E. Stillabower, M.D.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

No member of the Compensation Committee is currently, or has formerly been, an officer or employee of the Company or any of its subsidiaries. The Company had no relationship during 2017 requiring disclosure under Item 404 of Regulation S-K with respect to any of the persons who served on the Compensation Committee during 2017.

GOVERNANCE COMMITTEE MEMBERS

- F. Ann Millner, Ed.D. (Chair)
- A. Scott Anderson
- Michael E. Stillabower, M.D.
- David M. Liu, M.D.
- Kent W. Stanger

The Governance Committee met three times during 2017.

19 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

Risk Management

The Board is involved in assessing and managing risks that could affect the Company. One of the roles of the Board is to periodically assess the processes utilized by management with respect to risk assessment and risk management, including identification by management of the principal risks of our business, and the implementation by management of appropriate systems to deal with such risks. The Board fulfills these responsibilities either directly, through delegation to committees of the Board, or, as appropriate, through delegation to individual directors.

When the Board determines to delegate any risk management oversight responsibilities, typically such delegation is made to the applicable standing committee(s) of the Board. The Audit Committee is generally responsible for oversight of risks such as those relating to the quality and integrity of our financial reports, the independence and qualifications of our independent registered public accounting firm, our compliance with disclosure and financial reporting requirements

and overall enterprise risk management. The Governance Committee is generally responsible for oversight of risks addressed through the identification and recommendation of individuals qualified to become directors of the Company, director and management succession planning and development and implementation of corporate governance principles. The Compensation Committee is generally responsible for oversight of risks such as those relating to executive employment policies and our compensation and benefits systems. These committees exercise their oversight responsibilities through reports from and meetings with officers of the Company responsible for each of these risk areas, including our Chief Financial Officer, Chief Legal Officer, Chief Compliance Officer and Director of Internal Audit. In such meetings, committee members discuss and analyze such risks, and, when necessary, consult with outside advisors.

Shareholder Communication with the Board of Directors

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Board will receive communications from Company shareholders. All communications, except those related to shareholder proposals that are discussed below under the heading Shareholder Proposals for Annual Meeting 2019, must be sent to our Corporate Secretary (Brian G. Lloyd) at our principal executive offices at 1600 West Merit Parkway, South Jordan, UT 84095. Communications submitted to the Board (other than communications received through our whistleblower

hotline, which are reviewed and addressed by the Audit Committee) are generally reported to our directors at the next regular meeting of the Board.

All directors of the Company are strongly encouraged to attend our annual meetings of shareholders. Eight of the nine directors then serving on the Board were present at our 2017 annual meeting of shareholders.

Governance Guidelines and Code of Ethics

Governance Guidelines

The Governance Guidelines set forth the responsibilities of our directors.

The Governance Guidelines were amended in May 2016 to require each director to submit a letter of resignation upon reaching 75 years of age, which resignation becomes effective at the next succeeding annual meeting of shareholders and will be accepted by the Board absent a determination

by the Governance Committee or the entire Board to nominate the director for an additional term.

The Governance Guidelines were further amended in October 2017 to include director stock ownership guidelines that, among other things, require directors to maintain minimum stock ownership equal to at least three times the annual retainer received. The Board expects directors to meet this requirement by December 31, 2020. The Governance Committee will determine compliance and may allow waivers on a case-by-case basis.

Table of Contents

Corporate Governance and Related Matters

GOVERNANCE MATERIALS

The following materials relating to corporate governance are available via our website at:

www.merit.com/investors/corporate-governance/

• Code of Business Conduct and Ethics	• Compensation Committee Charter
• Corporate Governance Guidelines	• Nominating and Corporate Governance Committee Charter
• Audit Committee Charter	

Code of Business Conduct and Ethics

Our Code of Business Conduct and Ethics ([Code of Conduct](#)) applies to our directors and employees, including the principal executive, financial and accounting officers, and is supplemented by additional provisions applicable to our CEO and senior financial and accounting officers. All Merit directors, officers and employees are required to act ethically at all times and in accordance with the principles and policies set forth in the Code of Conduct.

Among other principles and policies, the Code of Conduct finds a conflict of interest exists when a person's private interest interferes in any way with the interests of the Company. The Code of Conduct recognizes that a conflict of interest occurs when the Company enters into a transaction in which an employee, officer, or director, or someone related to or affiliated with an employee, officer, or director, has a significant personal interest. The Code of Conduct also recognizes that a conflict of interest arises when an employee, officer or director of the Company receives an improper benefit as a result of the person's position with the Company and prohibits any form of loan or credit to directors or officers of the Company or their family members.

The Code of Conduct obligates employees, officers and directors to promptly disclose conflicts of

interest to a supervisor, management, or the Board. Any directors who have a conflicting interest in a potential conflicting interest transaction may not participate in the review of that transaction by the Board. Any waiver of the Code of Conduct may be made only by the Board and is required to be promptly disclosed as required by law or the regulations of any exchange on which our securities are traded, including NASDAQ.

Whistleblower Hotline

As contemplated by the Code of Conduct, we have established a whistleblower hotline that enables our employees, vendors, customers, and shareholders, as well as other interested parties, to submit confidential and anonymous reports of suspected or actual violations of the Code of Conduct.

Our whistleblower hotline may be accessed:

- by telephone at (877) 874-8416
- online at www.merit.alertline.com

The Audit Committee regularly reviews all complaints we receive through the whistleblower hotline.

Securities Trading Restrictions

We have adopted a corporate policy regarding trading in our Common Stock ([Insider Trading Policy](#)) which is applicable to all of our directors and officers, as well as certain other Merit employees who are most likely to have access to material, non-public information regarding our business operations and financial condition ([Insiders](#)). The Insider Trading Policy imposes restrictions on Insiders with respect to transactions which may violate federal or state securities laws. Among its provisions, the Insider Trading Policy prohibits trading in Our Common Stock on a short-term basis, engaging in short sales of Our Common Stock and purchasing or selling options in Our Common Stock.

21 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

NON-EMPLOYEE

DIRECTOR COMPENSATION

We use a combination of cash and stock-based incentive compensation to attract and retain qualified candidates to serve as directors. In setting director compensation, the Board considers the significant amount of time that directors expend in fulfilling their duties to the Company as well as the skill level required by the Company of its directors.

Cash Compensation Paid to Directors

For the year ended December 31, 2017, all non-employee directors of the Company (except Nolan E. Karras) received an annual cash retainer of \$60,000. Mr. Karras, as lead independent director, received an annual cash retainer of \$110,000.

Committee-specific retainers are set forth in the opposite schedule.

SCHEDULE OF DIRECTOR RETAINERS		
Lead Independent Director		\$110,000
Other Directors		\$60,000
Audit Chair		\$20,000
Audit Member		\$10,000
Compensation Chair		\$15,000
Compensation Member		\$7,500
Governance Chair		\$10,000
Governance Member		\$5,000

Directors are also reimbursed for (a) out-of-pocket travel and related expenses incurred in attending Board and committee meetings and other Company events, and (b) up to \$5,000 for annual educational expenses.

Stock Awards

Directors are eligible to participate in our equity incentive programs. During the year ended December 31, 2017, each non-employee director received an award of options under the 2006 Incentive Plan to purchase 25,000 shares of Common Stock at an exercise price

of \$34.40 per share, the per share market closing price on the date of the grant. Director stock options vest over five years at the rate of 20% per year.

The following table shows amounts paid to each of our non-employee directors in 2017.

NON-EMPLOYEE DIRECTOR SUMMARY COMPENSATION

Name (1)	Fees Earned or Paid in Cash (\$)	Options Awards (2)	Non-Equity Incentive Plan Compensation (\$)	All Other Compensation (\$)	Total Compensation (\$)
A. Scott Anderson	80,000	282,170			362,170
Thomas J. Gunderson (3)	70,000	282,170		5,000	357,170
Nolan E. Karras	130,000	282,170			412,170
Franklin J. Miller, M.D.	77,500	282,170			359,670
F. Ann Millner, Ed.D.	70,000	282,170			352,170
David M. Liu, M.D.	65,000	282,170			347,170
Kent W. Stanger	65,000	282,170			347,170
Michael E. Stillabower, M.D.	72,500	282,170			354,670

(1) Fred P. Lampropoulos served as a director of the Company during 2017 but is not identified in the foregoing director summary compensation table because of his dual status as an NEO and director. Information regarding Mr. Lampropoulos's 2017 compensation can be found under "Executive Compensation and Related Matters" below.

Table of Contents

CORPORATE GOVERNANCE AND RELATED MATTERS

(2) The amounts shown for the option awards reflect the aggregate grant date fair value of all equity awards granted to the non-employee directors in 2017. We calculated these amounts in accordance with financial statement reporting rules, using the same assumptions we used for financial statement reporting purposes pursuant to our long-term incentive plans. Assumptions used in the calculation of these amounts are included in footnotes to our 2017 audited financial statements. As of December 31, 2017, each non-employee director had outstanding options for the following number of shares: Mr. Anderson, 79,000; Mr. Gunderson, 25,000; Mr. Karras, 125,000; Dr. Miller, 155,000; Dr. Millner, 57,739; Dr. Liu, 46,000; Mr. Stanger, 103,375; and Dr. Stillabower, 165,000.

(3) Prior to his appointment as a director of the Company, Mr. Gunderson provided financial consulting services to the Company on a limited basis. The amount shown for Mr. Gunderson reflects a consulting payment in the amount of \$5,000 paid to Mr. Gunderson prior to his appointment as a director.

RELATED PERSON

TRANSACTIONS

Policies and Procedures Regarding Transactions with Related Persons

Our Code of Conduct requires that every employee avoid situations where loyalties may be divided between our interests and the employee's own interests. Employees and directors must avoid conflicts of interest that interfere with the performance of their duties or are not in our best interests.

Pursuant to its written charter, the Audit Committee reviews and approves all related party transactions (as such term is used by ASC Topic 850 Related Party Disclosures) involving executive officers and directors, or as otherwise may be required to be disclosed in our financial statements or periodic filings with the Securities and Exchange Commission (the [SEC](#)) (including under Item 404 of Regulation S-K under the Securities Act of 1933), other than:

(a) grants of stock options made by the Board or any committee thereof or pursuant to an automatic grant plan; and

(b) payment of compensation authorized by the Board or any committee thereof.

A **Related Person Transaction** is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the

Company (including any of its subsidiaries) was, is or will be a participant and, as relates to directors or shareholders who have an ownership interest in the Company of more than 5%, the amount involved exceeds \$120,000, and in which any Related Person (defined below) had, has or will have a direct or indirect material interest.

A **Related Person** includes officers, directors, nominees, five percent beneficial owners and their respective immediate family members (which in turn includes person's spouse, parents, siblings, children, in-laws, step relatives, and any other person sharing the household (other than a tenant or household employee)).

Related Person Transactions include transactions between the Company and its executive officers and directors. We have adopted written policies and procedures regarding the identification of Related Persons and Related Person Transactions and the approval process for such transactions. The Audit Committee considers each Related Person Transaction in light of the specific facts and circumstances presented, including but not limited to the risks, costs and benefits to the Company and the availability from other sources of comparable services or products.

23 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

Certain Related Person Transactions

The Board, acting through the Audit Committee, believes that the following Related Party Transactions are reasonable and fair to the Company:

- Joseph C. Wright, President of Merit International, a division of the Company, is the brother-in-law of Fred P. Lampropoulos, Chair of the Board, CEO and President of the Company. In 2017, we provided to Mr. Wright total cash and equity compensation of \$943,467.

- Justin J. Lampropoulos, Executive Vice President of Sales, Marketing & Strategy of the Company, is the son of Fred P. Lampropoulos, Chair of the Board, CEO and President of the Company. In 2017, we provided to Mr. Justin Lampropoulos total cash and equity compensation of \$785,801.

- Charles Wright, Director of Business Development of the Company, is the brother-in-law of Fred P. Lampropoulos, Chair of the Board, CEO and President of the Company. In 2017, we provided to Mr. Wright total cash and equity compensation of \$555,006.

- Anne-Marie Wright, Vice President of Corporate Communications of the Company, is the wife of Fred P. Lampropoulos, the Chair of the Board, CEO and President of the Company. During the year ended December 31, 2017, we paid to Ms. Wright total compensation of \$162,226.

- Frank Wright, OEM Business Development Manager of the Company, is the brother-in-law of Fred P. Lampropoulos, Chair of the Board,

CEO and President of the Company. In 2017, we paid to Mr. Wright total compensation of \$208,529.

- Before his appointment as a director, Dr. David M. Liu was engaged from time to time as a consultant to the Company on a contract basis. Dr. Liu also has received payments under the terms of a technology license agreement dated August 1, 2014 (the [License Agreement](#)) from the Company to license technology created by Dr. Liu and one of his colleagues. During 2016, and before his appointment as a director, Dr. Liu received approximately \$50,000 pursuant to the terms of the License Agreement. During 2015, the Company paid Dr. Liu approximately \$9,000 in his role as an external consultant. It is possible that Dr. Liu may provide additional services in this capacity in the future, and future payments to Dr. Liu, in the form of consulting fees, royalties, and lump-sum milestone payments, may be made. The terms of the License Agreement and the consulting arrangement with Dr. Liu described above were negotiated in arms-length transactions.

- Prior to his appointment as a director, Thomas J. Gunderson provided financial consulting services to the Company on a limited basis. During 2017, and before Mr. Gunderson's appointment as a director, the Company paid Mr. Gunderson approximately \$5,000 as remuneration for such services. The Company

does not intend to pay any such fees to Mr. Gunderson during his service as a director.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

EXECUTIVE SUMMARY

We are a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. We have delivered year-over-year revenue growth and maintained profitability since 1990.

The Compensation Committee believes there are multiple factors that have contributed to our strong record of financial and operating performance, but two of the key factors have been our outstanding employees and the leadership provided by our executive officers. Accordingly, the Compensation Committee seeks to implement and advance an executive compensation program that recognizes Company performance and individual contribution, while encouraging long-term motivation and retention. The Compensation Committee believes our executive compensation program has been instrumental in helping the Company sustain its strong financial performance over many years.

Under the oversight of the Compensation Committee, our compensation philosophy is to offer compensation programs to the NEOs that align the interests of management and shareholders for the purpose of maximizing shareholder value, while considering the interests of other significant stakeholders such as employees, customers, business partners and the communities in which we operate. Among other

objectives, those programs are designed to:

- focus executives on achieving or exceeding measurable performance targets;
- influence executives to lead our employees in the implementation of cost saving plans;
- continue our entrepreneurial spirit;
- attract and retain highly-qualified and motivated executives; and
- promote a highly ethical environment and maintain health and safety standards

Our executive compensation programs specific to the NEOs are overseen by the Compensation Committee. In pursuit of our compensation philosophy and objectives, the Compensation Committee believes that the compensation packages provided to the NEOs should generally include both cash and equity-based compensation, generally in the form of stock options. Base pay and benefits are set at levels considered necessary to attract and retain qualified and effective executives. Variable incentive pay is used to align the compensation of the NEOs with our short-term business and performance objectives, such as income and overall financial performance. Equity awards have historically been used to retain key employees and to motivate executives to create long-term shareholder value.

SELECTED 2017 HIGHLIGHTS

- Successful completion of three-year plan to accelerate growth and improve profitability and extension of the plan for two additional years
- Achievement of net sales, non-GAAP gross margin, and GAAP and non-GAAP earnings per share financial performance objectives
- Completed multiple significant acquisition transactions, including the critical care division of Argon Medical Devices, Inc. and Catheter Connections, Inc., with expanded Merit presence in Asia Pacific
- Completed transition to limited direct sales model in Japan, designed to increase Merit responsiveness and profitability
- Cumulative total return on our Common Stock from December 31, 2012 to December 31, 2017 of 211% (1)

(1) See Item 5 of our Annual Report on Form 10-K filed on March 1, 2018. Past results are not necessarily an indicator of future results.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Named Executive Officers

In addition to Mr. Lampropoulos (whose biography is included under Proposal 1: Election of Nominee Directors), we have included below information related to our NEOs:

BERNARD J. BIRKETT

**Chief Financial Officer
and Treasurer**

Age: 49

Current Position Since: November 2015

Education: B.Comm, National University of Ireland Galway; MSc Finance, Michael Smurfit Graduate Business School at University College Dublin; Strategic leadership program at Stanford's Graduate School of Business

Fellow Chartered and Certified Accountant

Highlights

- Previous positions at Merit include Executive Vice President of Finance, Vice President of International Finance, and Controller for Europe, the Middle East and Africa ([EMEA](#)), 2000 to 2015
- Before joining Merit, held accounting and finance related positions with several companies, including SPS Technologies, Inamed and Strix Ltd.

RONALD A. FROST

Chief Operating Officer

Current Position Since: January 2014

Education: Manufacturing Engineering Technology, AAS, Machine Tooling, Weber State University

Age: 56



Highlights

- More than 26 years of service to Merit and its shareholders
- Previous positions at Merit include Vice President (Materials and Operations), Quality Engineer, Manufacturing Engineer, Custom Kits Manager, Customer Service Manager, Production Planning and Warehouse Manager, General Manager of our Richmond, Virginia operations, and Vice President (Technology Transfer), 1991 to 2014

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

JOSEPH C. WRIGHT

**President,
International Division**

Age: 48

Current Position Since: July 2015

Education: B.A., (political science), Columbia University; M.B.A., (finance) Columbia University; Speaks Japanese

Mr. Wright is the brother-in-law of Fred P. Lampropoulos, Merit's CEO, President and Chair of the Board

Highlights

- Previous positions at Merit include (a) President, Technology Group overseeing Merit OEM, Merit Sensor Systems, Inc., and Merit's coating division, (b) Vice President of Marketing, and (c) Vice President, International responsible for sales in Canada, Asia Pacific, and Latin America, 2005 to 2015
- Manages businesses in all global markets outside the U.S. and EMEA
- Before joining Merit, held sales, marketing and business development positions with several companies, including Motorola and Micron

BRIAN G. LLOYD

**Chief Legal Officer,
Corporate Secretary**

Current Position Since: April 2016

Education: B.S. (finance), Brigham Young University; J.D., Columbia Law School

Age: 57



Highlights

- Practiced as an attorney, specializing in corporate governance, securities regulation and mergers and acquisitions, with the law firm of Parr Brown Gee & Loveless in Salt Lake City, Utah for more than 20 years.
- Also practiced law in those areas of specialization as a partner with the law firm of Stoel Rives, LLP for four years.

27 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

COMPENSATION DISCUSSION AND

ANALYSIS

This Compensation Discussion and Analysis is designed to explain our philosophy and objectives underlying our compensation policies, the processes we follow in setting compensation, and the components of compensation that we utilize in compensating our NEOs, who are listed below.

The Summary Compensation Table and other compensation tables under Executive Compensation Tables below should be read in conjunction with this section.

Fred P. Lampropoulos
Bernard J. Birkett
Ronald A. Frost
Joseph C. Wright
Brian G. Lloyd

Chair, President and Chief Executive Officer
Chief Financial Officer and Treasurer
Chief Operating Officer
President, International
Chief Legal Officer and Corporate Secretary

Process for Establishing Compensation

Procedure

The Compensation Committee has oversight responsibility for establishing compensation practices for our Chief Executive Officer ([CEO](#)) and the other NEOs.

Performance reviews of the CEO are conducted by the Compensation Committee based on our performance during a given year, compared with our performance objectives, as well as other factors intended to maximize short-term and long-term shareholder value.

Performance reviews of other NEOs are based on the CEO's evaluation of individual officer and Company performance for that year, with the objective of maximizing shareholder value. With respect to the compensation levels for the other NEOs, the Compensation Committee considers input and recommendations from the CEO. The CEO makes recommendations concerning salary adjustments, cash bonus programs and equity awards for the other NEOs, and the Compensation Committee considers those recommendations in determining the compensation of the other NEOs.

Role of Consultants

In prior years (most recently in 2015), the Compensation Committee has engaged Pearl Meyer & Partners ([Pearl Meyer](#)), an independent compensation consulting firm, to review our executive officer and director compensation practices and advise the Compensation Committee with respect to those compensation practices, including

salary, bonus, benefits and equity awards for our executive officers and retainers, meeting fees and equity awards for our directors, based on practices of our 2017 peer group companies. The Compensation Committee has evaluated Pearl Meyer's reports in prior years and, as they considered appropriate to achieve the best interests of the Company and its shareholders, implemented some of Pearl Meyer's recommendations.

In conducting its review of our compensation practices for 2017, the Compensation Committee did not engage Pearl Meyer. The Compensation Committee reviewed industry and peer compensation data for medical device companies included in published surveys issued by Radford, Aon Hewitt's medical device consulting group ([Radford](#)). During 2017, we participated in the Radford Global Technology Survey ([Radford Survey](#)), which includes 84 medical device companies with headquarters located in the United States. The Radford Survey, which we believe is generally considered a standard source of information for executive compensation, provides valuable information regarding industry and peer executive compensation practices. Our management utilizes the Radford Survey to determine the reasonableness of compensation for various levels of employees, including executives. The Compensation Committee also directed management to perform an internal review of Company executive compensation practices, as well as the executive compensation practices of other U.S. publicly-traded companies in the medical device industry.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Neither the Radford Survey nor the internal review yielded any significant concerns at the Compensation Committee level regarding our executive compensation practices.

Evaluation

In evaluating compensation of the NEOs for the year ended December 31, 2017, the Compensation Committee considered, among other factors, our performance and relative shareholder return in 2017, as compared to our performance targets for the 2017, and other factors considered relevant by the Compensation Committee.

Notwithstanding the Compensation Committee's use of the information supplied by Pearl Meyer in 2015, and information obtained from the Radford Survey and our management's review of executive compensation practices, the decisions of the Compensation Committee with regard to the NEOs for 2017 were based principally on objective and subjective evaluations of the individual NEOs.

Other Considerations

The Compensation Committee also relied on its experience and judgment in making executive compensation decisions after reviewing our performance on a quarterly and annual basis, and evaluating each NEO's individual performance and responsibilities with the Company, as well as current compensation arrangements. The compensation program for the NEOs and the Compensation Committee assessment process have been designed to be flexible in an effort to respond to the evolving business environment and individual circumstances relative to Company and individual performance, shareholder value, as well as internal equity for compensation levels among our executives.

Our executive compensation program is divided into the following two general categories:

- fixed pay; and

- variable pay.

Fixed pay consists of base salary and is intended to provide each NEO with a level of assured cash compensation appropriate for his or her position within the Company.

Variable pay includes annual cash bonus awards and equity-based awards in the form of stock options, each as explained in more detail below.

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Compensation Committee believes that a portion of total compensation of the NEOs should be both at-risk and tied to our achievement of its performance goals.

Generally, at the beginning of each year, the CEO identifies performance goals which are intended to align the efforts of our executive officers, including the NEOs, with our achievement of our strategic business plan to maximize shareholder value. The CEO then reviews those performance goals with the Compensation Committee. Those goals then become targets for the variable annual performance bonus component of our executive compensation program. Because the performance goals are generally established at the beginning of each year and market conditions fluctuate throughout the year, the performance goals may not correspond to subsequent annual earnings estimates released by the Company.

Compensation Committee Consideration of Shareholder Advisory Votes

At our annual meeting of shareholders held on May 24, 2017, we submitted the compensation of our executive officers to our shareholders in a non-binding vote. Our executive compensation program received the support of holders of approximately 56.1% of the shares represented at the meeting. The 56.1% support level was abnormally low, compared to our historical experience. For example, in 2016, 2015 and 2014, the number of shares voted in support of our executive compensation program were approximately 93.7%, 84.1% and 93.1%, respectively.

Given the abnormally low support registered for our executive compensation program at our 2017 annual meeting, the Compensation Committee undertook extensive discussions regarding the 2017 voting results among itself, with other members of the Board, with management and with shareholders of the Company. In the course of those discussions, the Committee received information that one of the principal factors which resulted in the abnormally low support of our executive compensation practices was a concern expressed by some of our shareholders and their advisors that our Employment Agreements contained provisions providing

for tax gross-up payments to our NEOs in connection with a change in control and change-in-control payments to our NEOs based solely upon the occurrence of a change in control of the Company.

Based upon those discussions, and after an extensive review of the concerns raised by our shareholders, as well as the corporate governance practices of other companies, the Compensation Committee recommended that the Board enter into discussions with the executive officers of the Company regarding amendment of the Employment Agreements to remove the features which appeared to cause concern for our shareholders. Based upon those discussions, on December 11, 2017 we entered into a First Amendment to Employment Agreement with each of the NEOs for the purpose of addressing the concerns identified by our shareholders. Following the execution of those amendments, we have no employment agreements with our NEOs that either include a parachute payment tax gross-up provision or allow any of the NEOs to qualify for change-in-control benefits solely upon a change in control. The Compensation Committee believes the amendment of the Employment Agreements is responsive to the concerns expressed by our shareholders and consistent with good corporate governance practices.

29 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Pay Mix

The allocation between cash and non-cash NEO compensation is influenced by the practices of subjective and objective analysis conducted by the Compensation Committee, and is intended to reflect the Compensation Committee's determination of the appropriate compensation mix among base pay, annual cash incentives and long-term equity incentives. Actual cash and equity-based incentive awards are determined based on the performance of the Company or the individual NEO, depending on the position of the NEO, the type of award and our performance, compared to established goals.

For 2017, the elements of the compensation mix for the NEOs included:

- base salary (designed to attract and retain executives over time);
- annual performance bonus (designed to focus on business objectives established by the Compensation Committee for a particular year);
- long-term equity-based incentive compensation in the form of stock option awards (designed to further align NEO pay with performance);
- broad-based employee retirement, welfare and fringe benefits programs, and other personal benefits; and
- executive deferred compensation.

Fixed Compensation

Base Salary. The Compensation Committee does not use a specific formula for evaluating individual performance of the NEOs. The performance of the NEOs other than the CEO is assessed by the Compensation Committee taking into account the CEO's input regarding each NEO's contributions to our performance for the applicable year. The CEO's performance is assessed by the Compensation Committee in formal and informal meetings with the CEO, as well as executive sessions conducted by the Compensation Committee.

The criteria used in setting the base salary for each NEO, including the CEO, vary depending on the NEO's function, but generally include the Compensation Committee's assessment of the NEO's:

- advancement of our interests with shareholders and customers and in other strategic business relationships;
- achievement of our financial results;
- position and experience (in an effort to avoid gender or age discrimination);

Among the factors the Compensation Committee considered when establishing NEO base salaries for 2017 were:		
Fred P. Lampropoulos		
•	our 2016 financial performance;	
•	successful completion of acquisition transactions and integration of acquired enterprises and products;	
•	operational management, including cost savings, product development (including inventions and patent prosecution), international expansion, subsidiary development, risk management, and manufacturing capacity planning;	
•	shareholder relations; and	
•	strategic business development, management development and oversight, and impact on overall shareholder value.	
Bernard J. Birkett		
•	our 2016 financial results;	
•	responsibility for the financial affairs of an increasingly large and complex organization;	
•	shareholder relations;	
•	oversight of our cash flow and budgeting practices; and	
•	accounting for, and financing of, acquired enterprises and products.	
Ronald A. Frost		
•	conducting our worldwide operations within the budget established by the Board;	
•	helping to integrate acquired enterprises and products; and	
•	efforts to achieve cost savings throughout our operations.	
Joseph C. Wright		
•	management of our international division, including oversight of our international growth and sales;	
•	identifying potential new markets for expansion and growth and development of our international sales strategy; and	
•	budget management.	
Brian G. Lloyd		
•	oversight of our legal department, with responsibility for supporting our worldwide operations;	
•	corporate counsel and support of the Board in fulfilling its corporate governance obligations; and	
•	negotiation and coordination of acquisition and financing transactions.	

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

- leadership inside and outside the Company;
- contribution to our product quality and development; and
- advancement in skills and responsibility.

Given the subjective nature of the criteria identified above, the Compensation Committee has not attempted to develop numeric measurements in determining base salaries for the NEOs. Instead, the Compensation Committee establishes base salaries at levels commensurate with the Compensation Committee's evaluation of each NEO's contribution to our business success.

Based on its evaluation, the Compensation Committee approved the following NEO base salaries for the year ended December 31, 2017, which are also reflected in the Summary Compensation Table under Executive Compensation Tables below.

NAMED EXECUTIVE OFFICER	BASE SALARY
Fred P. Lampropoulos	\$ 1,412,308
Bernard J. Birkett	\$ 514,687
Ronald A. Frost	\$ 400,000
Joseph C. Wright	\$ 473,078
Brian G. Lloyd	\$ 515,385

(1) Base salary amounts reflect amounts paid to the NEOs as reported in the Summary Compensation Table shown on page 45. Base salary amounts as of December 31, 2017, as approved by the Compensation Committee were: Mr. Lampropoulos, \$1,700,000; Mr. Birkett, \$500,000; Mr. Frost, \$400,000, Mr. Wright, \$500,000; and Mr. Lloyd, \$600,000.

Broad-Based Benefits Programs

We offer multiple broad-based benefits programs to our employees, including our NEOs. Those programs include benefits such as health, dental, vision, disability and life insurance, health savings accounts, health care reimbursement accounts, employee stock purchase plan, paid vacation time and discretionary Company contributions to a 401(k) profit sharing plan.

Benefits are provided to our executives in accordance with practices the Compensation Committee believes

are consistent with industry standards. The Compensation Committee believes such benefits are a necessary element of compensation in attracting and retaining employees. In addition, the NEOs receive limited perquisites in an attempt to achieve a competitive pay package, as further detailed in the Summary Compensation Table.

Deferred Compensation Plan

We provide a non-qualified deferred compensation plan for the benefit of certain of our highly-compensated management employees, including the NEOs. Under the non-qualified deferred compensation plan, eligible executives may elect in advance of each calendar year to defer up to 100% of their cash salary and bonus compensation earned with respect to such year. Amounts deferred are credited to an unfunded liability account maintained by the Company on behalf of the applicable NEO, which account is deemed invested in and earns a rate of return based upon certain notational and self-directed investment options offered under the plan. In our discretion, we may elect to credit each eligible participant's account under the deferred compensation plan with an employer matching contribution but, to date, we have never elected to do so. Participant account balances under the deferred compensation plan are fully-vested and will be paid by the Company to each participant upon retirement or separation from employment, or on other specified dates, in a lump sum or in installments according to a schedule elected in advance by the participant.

The Company and its subsidiaries do not maintain any other executive pension or retirement plans for the NEOs.

Variable Compensation

In general, our variable compensation programs are designed to align the interests of our executive officers, including the NEOs, with our operating and financial results.

Annual Performance Cash Bonuses

Our general practice is to provide NEOs with the opportunity to earn annual performance bonus compensation under a program that recognizes attainment of key objectives. The key objectives that underlie our annual incentive compensation programs are established annually by the Compensation Committee based upon

31 **2018 PROXY STATEMENT** / www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

recommendations made by the CEO, and may vary between years and between NEOs, but generally include objectives that reward attainment of targeted sales, earnings, gross margins and cost savings.

In setting the performance bonus amounts that an NEO is eligible to earn for achieving specified objectives, the Compensation Committee and the CEO consider bonus and total cash compensation levels for each NEO. Although bonus opportunities for achieving objectives are generally established for each NEO based on job scope and contribution, the Compensation Committee retains discretion to positively or negatively adjust performance bonus amounts based on factors that are not included in the pre-determined objectives. NEOs also have the opportunity to earn additional discretionary bonuses for extraordinary performance, as determined by the Compensation Committee.

The decision as to whether to provide an annual performance bonus program to any NEO for any year, the type and funding of any program offered, and the objectives that underlie any program, are subject to the discretion of the Compensation Committee based on the recommendation of the CEO and industry-specific conditions existing during the applicable year. The Compensation Committee may also exercise positive or negative discretion based on its assessment of the individual NEO's contribution and accountability

for the objectives that are the subject of the bonus recommendations from the CEO and any other factors the Compensation Committee considers relevant.

For 2017 (and after considering the CEO's recommendations), the Compensation Committee established incentive cash bonus objectives for Messrs. Lampropoulos and Wright, but did not establish specific incentive cash bonus objectives for other NEOs. The incentive cash bonus objectives for Mr. Lampropoulos were based on sales, gross margins (calculated on a GAAP and non-GAAP basis), and earnings per share (calculated on a GAAP and non-GAAP basis). The incentive cash bonus objectives for Mr. Wright were based on sales of the Company's products in all global markets other than the U.S. and EMEA.

The specific 2017 goals established by the Compensation Committee for Mr. Lampropoulos in the performance bonus categories, together with the level of our actual 2017 performance in those categories, are as follows.

PERFORMANCE BONUS OBJECTIVES	2017 GOALS	2017 RESULTS
Sales	\$722 727 million	\$727.9 million
Gross Margin (GAAP)	45.0 45.5%	44.8%
Gross Margin (Non-GAAP) (1)	48.0 48.5%	48.1%
Earnings Per Share (GAAP)	\$0.55 - \$0.61	\$0.55
Earnings Per Share (Non-GAAP) (2)	\$1.23 - \$1.28	\$1.28

(1) Non-GAAP Gross Margin is calculated by adjusting gross profit by amounts recorded for amortization of intangible assets, inventory mark-up related to acquisitions and severance expense. See Non-GAAP Financial Measures in this Proxy Statement for additional information.

(2) Non-GAAP Earnings Per Share is calculated as GAAP net income excluding intangible amortization expense, acquisition related costs, intangible asset impairment charges, contingent consideration benefits, certain legal expenses, and severance costs. All excluded items are tax affected and total Non-GAAP net income is divided by the weighted average diluted shares outstanding. See Non-GAAP Financial Measures in this Proxy Statement for additional information.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

The specific 2018 goals for Mr. Lampropoulos in the performance bonus categories align with the guidance we issued on February 28, 2018.

With respect to Mr. Wright, the Compensation Committee approved performance bonus objectives based on the following sales targets for our international operations for which Mr. Wright has supervisory responsibility.

2017 GOAL	2017 RESULTS
\$141.6 million	\$155.7 million

Although the Compensation Committee did not establish specific 2017 incentive cash bonus objectives for Messrs. Birkett, Frost and Lloyd, the Compensation Committee based its determination of discretionary bonuses (see **Discretionary Bonuses** below) paid to Messrs. Birkett, Frost and Lloyd upon the Company's achievement of the annual cash bonus objectives established for Mr. Lampropoulos. The Compensation Committee believes that the annual cash bonus objectives provided meaningful motivation to Mr. Lampropoulos and the other NEOs and were instrumental in influencing Company performance during 2017.

The Compensation Committee's evaluation of our achievement of the performance bonus goals shown above indicated that we achieved the goals established for sales, non-GAAP gross margins, GAAP earnings per share and non-GAAP earnings per share. The Company did not achieve the goal for GAAP gross margins. The Compensation Committee noted, however, that a principal factor which contributed to our failure to achieve the goal for GAAP gross margin was the variability in GAAP gross margin associated with acquisition and integration costs we incurred in connection with multiple acquisition transactions we completed during 2017, including the critical care division of Argon Medical Devices, Inc. and Catheter Connections. The Compensation Committee recognized that those acquisition transactions were undertaken consistent with our growth strategy, were approved by the Board, and reflected the Board's belief that the transactions would increase shareholder value in the long term, but would result in significant unbudgeted expenses in the short term. Based upon its assessment of the Board's objective of increasing shareholder value, the Compensation Committee determined to award to

Mr. Lampropoulos the full amount of the annual cash bonus objective established for him.

Discretionary Bonuses

In addition to the cash bonus opportunities under the performance bonus program described above, the Compensation Committee (with the input of the CEO) may choose to reward extraordinary performance and achievements by awarding discretionary bonuses to the NEOs and other executives from time to time that are not part of the annual incentive plan or any other plan. Based upon the Compensation Committee's review of the performance bonus objectives discussed above, and following a review of the performance of each of Messrs. Lampropoulos, Birkett, Frost and Lloyd, the Compensation Committee determined to grant discretionary bonuses to each of those NEOs in the amounts set forth in Summary Compensation Table set forth on page 45. There is no standing expectation that all (or any) NEOs will receive discretionary performance bonuses in any particular year, and the criteria for such bonuses are not established in advance.

Long-Term Incentive Compensation

Historically, long-term equity awards, in the form of stock options, have been granted at the Compensation Committee's discretion to the NEOs annually in an effort to provide long-term performance-based compensation, to encourage the NEOs to continue their engagement with the Company throughout the vesting periods, and to align management and shareholder interests.

In making awards under the 2006 Incentive Plan, the Compensation Committee considers grant size, the appropriate combination of equity-based awards, the impact of the grant on the our financial performance (as determined in accordance with the requirements of the Financial Accounting Standards Board ASC Topic 718 ([ASC Topic 718](#))), and the corresponding compensation value used by the Company in determining the amount of the awards (which may vary from the ASC Topic 718 expense).

Generally, the amount of long-term equity awards granted to the NEOs has been based upon the Compensation Committee's assessment of each NEO's expected future contributions to the Company and other factors. The amount or existence of those awards may

33 **2018 PROXY STATEMENT** / www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

also be influenced by external factors such as general economic or industry-specific conditions. We generally grant long-term equity awards at the regularly-scheduled Compensation Committee meeting held in February or May of each year, but may vary the date of grant from year to year.

During 2017, the Compensation Committee granted stock option awards to NEOs under the 2006 Incentive Plan in the following amounts:

NAMED EXECUTIVE OFFICER	NUMBER OF OPTIONS GRANTED
Fred P. Lampropoulos	200,000
Bernard J. Birkett	50,000
Ronald A. Frost	50,000
Joseph C. Wright	25,000
Brian G. Lloyd	50,000

Employment Agreements

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Compensation Committee has determined that executive employment agreements are necessary to provide competitive compensation arrangements to our NEOs, particularly because such agreements are common in our industry. Moreover, the Compensation Committee believes that the change in control provisions within the executive employment agreements help to retain the NEOs by reducing personal uncertainty and anxiety that may arise from the possibility of a future business combination.

We have entered into employment agreements (collectively, the [Employment Agreements](#)) with each of the NEOs. The annual base salaries payable under the Employment Agreements, as adjusted for 2017, were:

NAMED EXECUTIVE OFFICER	BASE SALARY
Fred P. Lampropoulos	\$ 1,412,308
Bernard J. Birkett	\$ 514,687
Ronald A. Frost	\$ 400,000
Joseph C. Wright	\$ 473,078
Brian G. Lloyd	\$ 515,385

(1) Base salary amounts reflect amounts paid to the NEOs as reported in the Summary Compensation Table shown on page 45. Base salary amounts as of December 31, 2017, as approved by the Compensation Committee were: Mr. Lampropoulos, \$1,700,000; Mr. Birkett, \$500,000; Mr. Frost, \$400,000, Mr. Wright, \$500,000; and Mr. Lloyd, \$600,000.

The amount of the base salary payable to each NEO may be subject to change based on review by the Compensation Committee on an annual basis. Although the employment status of each of the NEOs is at will, the Employment Agreements provide for mandatory severance payments to each NEO in the event the

NEO's employment terminates for certain reasons in connection with a Change in Control (as defined below). Those severance arrangements are discussed in greater detail below under the heading Executive Compensation Tables Potential Payments upon Termination or Change in Control.

In addition to the annual base salary described above, the Employment Agreements also allow the NEOs to receive an annual cash bonus payment in an amount to be determined in the sole discretion of the Board (which has delegated that authority to the Compensation Committee). Notably, in fiscal years ending after a Change in Control, the annual bonus must be at least equal to an NEO's average annual cash bonus for the last three full fiscal years ending prior to the Change in Control.

The NEOs (and to the extent applicable, their spouses and eligible dependents) are eligible to participate in all incentive, savings and retirement, health insurance, term life insurance, long-term disability insurance, deferred compensation, employee stock purchase and other employee benefit plans, policies or arrangements we maintain for our employees generally and, at the discretion of the Compensation Committee, in the 2006 Incentive Plan and other benefit plans maintained by the Company for our executives.

The terms of the Employment Agreements reflect in part the concern of the Compensation Committee that a future threatened or actual change in control, such as through an acquisition or merger, could cause disruption and harm to the Company in the event of the resulting loss of any of its key executives. The change in control provisions in the Employment Agreements are intended to provide a measure of incentive and security to our key

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

executives until the resolution of any such threatened or actual change in control. However, the Compensation Committee believes that such agreements should not include provisions that would obligate a potential acquirer of the Company to make large payouts to the NEOs simply because a change in control has occurred. Because of this concern, the occurrence of a change in control event alone will not trigger any payment obligations to the NEOs under their respective Employment Agreements. Additional change in control payment obligations under the Employment Agreements

only arise in the event the NEO's employment is terminated without Cause in connection with the change in control or the NEO resigns for Good Reason (with each capitalized term in this sentence defined in the Employment Agreements and described under the heading Potential Payments Upon Termination or Change in Control Employment Agreements below) in connection with a change in control. Thus, the Compensation Committee regards the employment agreements as double trigger change in control agreements.

Tax Deductibility and Executive Compensation

Section 162(m) ([Section 162\(m\)](#)) of the Internal Revenue Code of 1986, as amended (the [Code](#)) imposes a \$1.0 million annual limit on the amount that a public company may deduct for compensation paid to a company's chief executive officer during a tax year or to any of the company's three other most highly compensated executive officers who are still employed at the end of the tax year. For tax years beginning before 2018, the limit does not apply to compensation that meets the requirements of Section 162(m) for qualified performance-based compensation (i.e., compensation paid only if the executive meets pre-established, objective goals based upon performance criteria approved by our shareholders).

The Compensation Committee reviews and considers the deductibility of executive compensation under Section 162(m) and attempts, to the extent practical, to implement compensation policies and practices that maximize the potential income tax deductions available to the Company including for tax years before 2018 by qualifying such policies and practices as performance-based compensation exempt from the deduction limits of Section 162(m).

In certain situations, the Compensation Committee may approve compensation that will exceed the deduction limitations of Section 162(m) in order to ensure competitive levels of total compensation for its executive officers. In such situations, the portion of the compensation payable to the executive officer that exceeds the \$1.0 million limit will not be deductible for tax purposes. Although deductibility of executive compensation for tax purposes is generally preferred, tax deductibility is not the sole objective of our executive compensation programs. The Company and the Compensation Committee believe that meeting the compensation objectives described above is more important than the benefit of being able to deduct the compensation for tax purposes.

All compensation paid to the NEOs, other than Mr. Lampropoulos, during 2017 was intended to be deductible under Section 162(m). Although Mr. Lampropoulos' compensation for 2017 exceeded the deduction limits of Section 162(m), the Compensation Committee approved that compensation amount in order to provide Mr. Lampropoulos with a compensation package that the Compensation Committee considers competitive and in the best interests of the Company and its shareholders.

35 **2018 PROXY STATEMENT** / www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Compensation Policies and Practices Relating to Risk Management

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Compensation Committee has reviewed our company-wide compensation program, which applies to all of our full-time employees, including the NEOs. Based on the Compensation Committee's review of the various elements of our executive compensation practices and policies, the Compensation Committee believes our compensation policies and practices are designed to create appropriate and meaningful incentives for our employees without encouraging excessive or inappropriate risk taking.

After undertaking this review, the Compensation Committee came to the following conclusions:

- Our compensation policies and practices are designed to include a significant level of long-term compensation, which discourages short-term risk taking;
- The base salaries we provide to our employees are generally consistent with salaries paid for comparable positions in our industry, and provide our employees with steady income while reducing the incentive for employees to take risks in pursuit of short-term benefits;
- Our incentive compensation is capped for some NEOs at levels established by the Compensation Committee, which it believes reduces the incentive for excessive risk-taking;
- We have established and adopted codes of ethics and business conduct, which are designed to reinforce the balanced compensation objectives established by the Compensation Committee; and
- We have adopted equity ownership guidelines for its executive officers, which the Compensation Committee believes discourages excessive risk-taking.

Based on the review outlined above, the Compensation Committee has further concluded that the risks arising from our compensation policies and practices for its employees are not reasonably likely to have a material adverse effect on the Company.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Additionally, at our annual meeting of shareholders held on May 24, 2017, our shareholders voted on an advisory basis with respect to the frequency of future advisory votes on executive compensation. Holders of approximately 77.1% of the shares represented at that meeting expressed their preference for an annual advisory vote. Consequently, we intend to hold an annual advisory vote on executive compensation until the next say-on-frequency vote at our annual meeting of shareholders in 2023.

The Compensation Committee will continue to review future shareholder voting results, including the voting results with respect to Proposal No. 3 - Advisory Vote on Executive Compensation, as described further in this Proxy Statement, and determine whether to make any changes to our executive compensation program in light of such voting results.

Compensation Committee Report

The Compensation Committee establishes and oversees the design and function of our executive compensation programs.

The members of the Compensation Committee have reviewed and discussed the foregoing Compensation Discussion and Analysis with the management of the Company and recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement.

<u>COMPENSATION COMMITTEE:</u>
A. Scott Anderson (Chair)
Franklin J. Miller, M.D.
Michael E. Stillabower, M.D.

PROPOSAL No. 3 ADVISORY VOTE ON EXECUTIVE COMPENSATION

Section 14A of the Exchange Act ([Section 14A](#)), which was enacted pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, requires that we provide shareholders with the opportunity to vote on an advisory (non-binding) resolution to approve the compensation of the NEOs disclosed in this Proxy Statement (colloquially referred to as a Say-on-Pay

Board recommendation

The Board unanimously recommends a vote FOR this proposal

proposal).

Accordingly, the following resolution will be submitted to our shareholders for approval at the Annual Meeting:

RESOLVED, that the Company's shareholders APPROVE, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's proxy statement for the 2018 Annual Meeting of Shareholders, pursuant to the compensation disclosure rules of the U.S. Securities and Exchange Commission, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosures.

As described above under the heading Compensation Discussion and Analysis, the Board believes our compensation of the NEOs achieves the primary goals of:

- focusing our executives on achieving or exceeding measurable performance targets;
- encouraging continuation of our entrepreneurial spirit;
- attracting and retaining highly-qualified and motivated executives;
- promoting our guiding principles for adherence to a high ethical environment, as well as health and safety standards; and

37 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

- aligning management compensation with shareholder value.

The Board encourages shareholders to review in detail the Compensation Discussion and Analysis beginning on page 28 of this Proxy Statement and the Executive Compensation Tables beginning on page 45 of this Proxy Statement. In light of the information set forth in such sections, the Board believes the compensation of the NEOs for the fiscal year ended December 31, 2017 was fair and reasonable and that our compensation programs and practices are in the best interests of the Company and our shareholders.

The advisory vote on this Say-on-Pay resolution is not intended to address any specific element of compensation; rather, the vote relates to all aspects of the compensation of the NEOs, as described in this Proxy Statement. While this vote is only advisory in nature, which means that the vote is not binding on the Company, the Board or the Compensation Committee

(which is composed solely of independent directors), the Board and the Compensation Committee value the opinion of our shareholders and will consider the outcome of the vote when addressing future compensation arrangements.

In the 2017 annual meeting of shareholders, held on May 24, 2017, our shareholders recommended that they be given an opportunity to vote on a Say-on-Pay resolution every year at our annual meeting of shareholders. Consequently, we intend to hold an annual advisory vote on executive compensation until the next say-on-frequency vote at our annual meeting of shareholders in 2023 (as required by Section 14A).

Approval of the resolution above (on a non-binding, advisory basis) requires that the number of votes cast at the Annual Meeting, in person or by proxy, in favor of the resolution exceeds the number of votes cast in opposition to the resolution.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

PROPOSAL NO. 4 APPROVE THE COMPANY'S NEW 2018 LONG-TERM INCENTIVE PLAN

Since 2006, the Company has maintained the 2006 Incentive Plan, which provides opportunities for employees, non-employee directors and other eligible participants to receive equity-based awards designed to align the interests of participants with the long-term objectives of the Company. Since the adoption of the 2006 Incentive Plan, we have amended the plan five times, in order to increase the number of shares of Common Stock available for the grant of awards under the plan (for a current total of 6,250,000), to extend the maturity of the 2006 Incentive Plan (to February 13, 2025) and for operational and administrative purposes.

After taking into account option awards with respect to 492,002 shares already granted in 2018 under the 2006 Incentive Plan, there are only approximately 2,290 shares available for future issuance under the 2006 Incentive Plan. The limited number of shares which remain available for issuance under the 2006 Incentive Plan would not be sufficient for anticipated future awards under the 2006 Incentive Plan. We are therefore requesting that our shareholders approve a new 2018 Long-Term Incentive Plan (the [2018 Incentive Plan](#)) to permit the Company to continue to grant awards.

Board recommendation

The Board unanimously recommends a vote FOR this amendment

We are seeking approval for 3.1 million shares under the 2018 Incentive Plan for future grants.

On April 2, 2018 the Board adopted the 2018 Incentive Plan and is recommending it for your approval at this year's Annual Meeting. If approved, the 2018 Incentive Plan will be the only compensation plan under which we grant stock options, restricted stock and other equity-based awards to our directors, officers, employees, and consultants going forward. These awards have enabled and will continue to enable Merit to attract and retain key employees and enable those employees to acquire and/or increase their proprietary interest in the Company, thereby aligning their interests with the interests of our shareholders.

In the event this proposal is approved by our shareholders, no further awards will be made under the 2006 Incentive Plan, but awards previously issued under the 2006 Incentive Plan would remain in effect. As of March 29, 2018, the closing sale price of the Common Stock on NASDAQ was \$45.35. If the 2018 Incentive Plan is not approved by shareholders, the 2006 Incentive Plan will remain in full force and effect in accordance with its terms.

Significant Historical Award Information

The following table provides information regarding the grant of equity awards under our 2006 Incentive Plan over the past three fiscal years:

KEY EQUITY METRIC	2017	2016	2015
Percentage of equity awards granted to NEOs (1)	28.90%	15.33%	28.61%
Equity burn rate (2)	2.59%	1.96%	1.39%
Dilution (3)	8.19%	10.12%	11.03%
Overhang (4)	7.21%	6.31%	5.44%

(1) Percentage of equity awards granted to individuals who were named executive officers in the relevant year is calculated by dividing the number of shares that were issuable pursuant to equity awards that were granted to NEOs during the year by the number of shares issuable pursuant to all equity awards granted during the year.

(2) Equity burn rate is calculated by dividing the number of shares issuable pursuant to equity awards granted during the year by the weighted average number of shares outstanding during the year, as disclosed in our Annual Report.

(3) Dilution is calculated by dividing the sum of (x) the number of shares issuable pursuant to equity awards outstanding at the end of the fiscal year and (y) the number of shares available under the 2006 Incentive Plan for future grants, by the number of shares outstanding at the end of the year.

(4) Overhang is calculated by dividing the number of shares issuable pursuant to equity awards outstanding at the end of the year by the number of shares outstanding at the end of the year.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

2018 Incentive Plan Summary

The following is a brief description of the principal features of the 2018 Incentive Plan. This summary is qualified in its entirety by reference to the full text of the 2018 Incentive Plan, which is included as [Exhibit 2](#) to this Proxy Statement.

Purpose. The purpose of the 2018 Incentive Plan is to assist the Company and our subsidiaries in attracting and retaining qualified individuals to serve as directors and employees of, and consultants and advisors to, the Company and our subsidiaries. The Board believes that the awards granted under the 2018 Incentive Plan will align incentives of such individuals and help us achieve our long-term objectives, which will in turn inure to the benefit of all of our shareholders.

Eligibility. Directors, employees, consultants and advisors of the Company and our subsidiaries will be eligible to receive awards under the 2018 Incentive Plan to the extent designated by the Compensation Committee or its delegate. The Compensation Committee has not yet determined who will receive awards under the 2018 Incentive Plan but future grants consistent with the Company's historical equity-based compensation practices are likely.

Administration. The 2018 Incentive Plan will be administered by the Compensation Committee. The Compensation Committee would have the authority to interpret and construe the provisions of the 2018 Incentive Plan and to make all decisions and determinations relating to the operation of the 2018 Incentive Plan, including the authority and discretion to:

- select the individuals to receive stock option grants or other awards;
- determine the time or times when stock option grants or other awards will be granted and will vest;
and
- establish the terms and conditions upon which awards may be exercised.

Subject to certain limitations, the Compensation Committee may delegate to the CEO authority to make stock option grants to employees other than executive officers and directors.

Duration. If approved by shareholders, the 2018 Incentive Plan would become effective on the date of the Annual Meeting and would continue for a term of ten

years from its effective date unless sooner terminated by the Board of Directors. No further awards would be granted under the 2018 Incentive Plan after that date.

Shares Subject to Plan. A maximum of 3,100,000 shares of Common Stock would be authorized for issuance under the 2018 Incentive Plan (including issuance pursuant to incentive stock options).

Any shares subject to options or stock appreciation rights would be counted against the shares available for issuance under the 2018 Incentive Plan (the Share Reserve) as one share for every share subject thereto. Any shares subject to awards other than options or stock appreciation rights are counted against the Share Reserve as two and one-half shares for every one share subject thereto. If an award under the 2018 Incentive Plan is forfeited or expires, the subject shares are again available for grant under the 2018 Incentive Plan (such forfeited or expired shares, Recycled Shares). To the extent that a share that was subject to an award that counted as one share against the 2018 Incentive Plan Share Reserve becomes a Recycled Share, the Share Reserve would be credited with (increased by) one share. To the extent that a share that was subject to an award that counted as two and one-half shares against the 2018 Incentive Plan Share Reserve becomes a Recycled Share, the Share Reserve is credited with two and one-half shares. The following types of shares of Common Stock would not be eligible to be granted again under the 2018 Incentive Plan:

- shares tendered by the participant, or withheld by the Company, to satisfy the purchase price of an option or any tax withholding obligation;

- shares which we repurchase with option proceeds; or

- shares subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof.

In the event the outstanding shares of Common Stock are increased, decreased, changed into, or exchanged for a different number or kind of shares or securities through reorganization, merger, recapitalization, reclassification, stock split, reverse stock split or similar transaction (a Recapitalization), the Share Reserve under the 2018 Incentive Plan will be proportionately adjusted.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Awards under the 2018 Incentive Plan

Like the 2006 Incentive Plan, the 2018 Incentive Plan provides for the following types of awards ([Awards](#)):

- (a) stock options;
- (b) stock appreciation rights;
- (c) restricted stock;
- (d) restricted stock units; and
- (e) other share-based awards.

Awards under the 2018 Incentive Plan may be granted as performance awards subject to conditions on exercise, vesting or payment that are tied to satisfaction of pre-determined financial or other performance goals designated by the Compensation Committee and set forth the applicable award agreements.

Stock Options. The Compensation Committee may from time to time award options to any plan participant subject to the limitations described above. Stock options give the holder the right to purchase shares of the Common Stock within a specified time at a specified price. Two types of stock options may be granted under the 2018 Incentive Plan, namely:

- incentive stock options ([ISOs](#)), which are subject to special tax treatment as described below and which are limited to employees of the Company and our subsidiaries; and
- non-statutory options ([NSOs](#)), which are available to all directors, employees, consultants and advisors of the Company and our subsidiaries.

The exercise price of an option cannot be less than the fair market value of a share of Common Stock at the time of grant. The expiration dates of options cannot be more than seven years after the date of the original grant.

Other than appropriate adjustments as described above to reflect a Recapitalization, the Compensation Committee may not without the approval of our shareholders:

- (a) lower the option price of an option after it is granted;

- (b) cancel an option when the option price exceeds the fair market value of the underlying shares in exchange for another Award; or
- (c) take any other action with respect to an option that may be treated as a repricing under the rules and regulations of NASDAQ.

Stock Appreciation Rights. The Compensation Committee may grant stock appreciation rights under the 2018 Incentive Plan to eligible participants. A stock appreciation right entitles the holder upon exercise to receive an amount in cash, shares of Common Stock, other property, or a combination thereof (as determined by the Compensation Committee), computed by reference to appreciation in the value of the Common Stock over its stated base value per share, which cannot be less than the fair market value of a share of Common Stock at the time of grant. The expiration dates of stock appreciation rights cannot be more than seven years after the date of the original grant.

Restricted Stock. The Compensation Committee may grant restricted shares of Common Stock under the 2018 Incentive Plan to such eligible participants, in such amounts, and subject to such terms and conditions (including the attainment of performance criteria) as the Compensation Committee determines in its discretion. Awards of restricted shares of the Common Stock may be made in exchange for services or other lawful consideration. Generally, awards of restricted shares of Common Stock are subject to the requirement that the shares be forfeited to the Company unless specified conditions are met.

Except for certain limited situations, grants of restricted shares of Common Stock will have a vesting period of not less than three years. Subject to these restrictions, conditions and forfeiture provisions, any recipient of an award of restricted stock will have all the rights of a shareholder of the Company, including the right to vote the shares upon grant subject to these restrictions, conditions and forfeiture provisions,.

Restricted Stock Units. The Compensation Committee may grant restricted stock units under the 2018 Incentive Plan having a value equal to a designated number of shares of Common Stock to such eligible participants, in such amounts, and subject to such terms and conditions (including the attainment of performance criteria) as the Compensation Committee determines in its discretion. If the requirements specified by the Compensation Committee are met, the grantee of such units will receive shares of Common Stock,

41 **2018 PROXY STATEMENT** / www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

cash, other property, or any combination thereof, equal to the fair market value of the designated number of shares of Common Stock.

Other Share-Based Awards. The Compensation Committee may also make other awards measured by the value of or payable in the form of shares under the 2018 Incentive Plan subject to the satisfaction of specified performance or other criteria. Other share-based awards may be paid in shares of Common Stock, cash, other property, or any combination thereof.

Accelerated Exercisability and Vesting on a Change in Control. Under the proposed 2018 Incentive Plan, all then outstanding awards will automatically become fully exercisable, vested and earned. Additionally, upon a Change in Control, the Company may elect to cancel all or any portion of then outstanding awards under the 2018 Incentive Plan in exchange for a payment equal to the fair market value of the cancelled awards. For this purpose, a Change in Control means:

- certain changes in the majority of the Board within a 12-month period;
- the acquisition by any person of 30% or more of the voting securities of the Company;
- consummation of a merger or reorganization of the Company in which neither the Company nor another entity controlled by our shareholders is the surviving entity;
- a sale or other disposition of all or substantially all of our assets to another entity that is not controlled by our shareholders; or
- shareholder approval of a liquidation of the Company.

Recoupment/Clawback. The Company will be entitled to the recoup compensation of whatever kind paid under the 2018 Incentive Plan by the Company at any time to the extent required by applicable securities or other law or as provided in any recoupment policy adopted by the Company.

Provisions for Foreign Participants. The Compensation Committee may modify awards granted to participants who are foreign nationals or employed outside the United States or establish, amend or rescind rules,

sub-plans or procedures under the 2018 Incentive Plan to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefits or other matters.

General Provisions. Unless authorized by the Compensation Committee in the agreement evidencing an award granted under the 2018 Incentive Plan, Awards may not be transferred other than by will or the laws of descent and distribution, and may be exercised during the participant's lifetime only by the participant or the participant's guardian or legal representative. The Board may, from time to time, alter, amend, suspend or terminate the 2018 Incentive Plan. Unless sooner terminated by the Board of Directors, the 2018 Incentive Plan will automatically terminate on the tenth anniversary of its effective date. No grants may be made under the plan following the date of termination, although grants made prior to that date may remain outstanding following the termination of the 2018 Incentive Plan until their scheduled expiration date.

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

Certain Federal Income Tax Consequences

The following is a brief summary of certain U.S. federal income tax consequences relating to awards under the 2018 Incentive Plan. This summary is made as of the date of this Proxy Statement, is not (and is not intended to be) complete, and does not describe state, local, foreign, or other tax consequences. The tax information summarized is not tax advice.

Tax Consequences to the Company

To the extent that a participant recognizes ordinary income in the circumstances described above, the Company or the subsidiary for which the participant performs services will be entitled to a corresponding deduction for tax purposes, but only if, among other things, the income:

- (a) meets the test of reasonableness;
- (b) is an ordinary and necessary business expense,
- (c) is not an excess parachute payment within the meaning of Section 280G of the Code; and
- (d) is not disallowed by the \$1 million limitation on executive compensation under Section 162(m).

Tax Consequences to Participants

Nonqualified Stock Options (NSOs). In general, for recipients of NSOs:

- (a) no income will be recognized by the participant at the time an NSO is granted;
- (b) at the time of exercise of an NSO, ordinary income will be recognized by the participant in an amount equal to the difference between the option price paid for the shares of Common Stock and the fair market value of the shares, if unrestricted, on the date of exercise; and
- (c) at the time of sale of shares of Common Stock acquired pursuant to the exercise of an NSO, appreciation (or depreciation) in value of the shares after the date of exercise will be treated as either short-term or long-term capital gain (or loss) depending on how long the shares have been held. For post-exercise appreciation in share value to qualify for long-term capital gain treatment, the shares must be held for more than one year from their date of issuance.

Incentive Stock Options (ISOs). No income will be recognized by a participant upon the grant to them of an ISO. In general, no income will be recognized

by the participant upon the exercise of an ISO for regular income tax purposes. However, the difference between the option price paid and the fair market value of the shares at exercise may constitute a preference item triggering alternative minimum tax on the participant. If shares of Common Stock are issued to a participant pursuant to the exercise of an ISO, and if no disqualifying disposition of such shares is made by such option holder within two years after the date of the grant or within one year after the transfer of such shares to the option holder, then upon later sale of such shares, any amount realized in excess of the option price will be taxed to the participant as long-term capital gain and any loss sustained will be a long-term capital loss.

If shares of Common Stock acquired upon the timely exercise of an ISO are disposed of prior to the expiration of either holding period described above, the participant generally will recognize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of such shares at the time of exercise (or, if less, the amount realized on the disposition of such shares if a sale or exchange) over the option price paid for such shares. Any further gain (or loss) realized by the participant generally will be taxed as short-term or long-term capital gain (or loss) depending on the holding period.

Stock Appreciation Rights. No income will be recognized by a participant in connection with the grant of a stock appreciation right. When the appreciation right is exercised, the participant normally will be required to include as taxable ordinary income in the year of exercise an amount equal to the amount of cash received and the fair market value of any unrestricted shares of Common Stock or other property received on the exercise.

Restricted Stock. The recipient of restricted shares of Common Stock generally will not be subject to tax until the shares are no longer subject to forfeiture or restrictions on transfer for purposes of Section 83 of the Code (the **Restrictions**). At such time, the participant will be subject to tax at ordinary income rates on the then fair market value of the restricted shares (reduced by any amount paid by the participant for such restricted shares). However, a participant who makes an election under Section 83(b) of the Code within 30 days of the date of transfer of the shares will have taxable ordinary

43 **2018 PROXY STATEMENT** / www.merit.com

Table of Contents

EXECUTIVE COMPENSATION AND RELATED MATTERS

income on the date of transfer of the shares equal to the excess of the fair market value of such shares (determined without regard to the Restrictions) over the purchase price, if any, of such restricted shares.

Any appreciation (or depreciation) after the date the value of the restricted shares initially becomes taxable to the participant which the participant later realizes upon a subsequent disposition of such shares will be treated as long-term or short-term capital gain (or loss) depending upon how long the shares have been held. If a Section 83(b) election has not been made, any dividends received with respect to restricted shares that are subject to the restrictions generally will be treated as deferred compensation that is taxable as ordinary income to the participant.

Restricted Stock Units. Generally, no income will be recognized by a participant upon the award of

restricted stock units. The recipient of a stock unit award generally will be subject to tax at ordinary income rates on any cash received and the fair market value of any unrestricted shares of Common Stock or other property on the date that such amounts are transferred to the participant under the award (reduced by any amount paid by the participant for such restricted stock units).

Other Share-Based Awards. No income generally will be recognized by a participant upon the grant of other Share-Based Awards until such awards become vested and payable. Upon payment in respect of other Share-Based Awards, the recipient generally will be required to include as taxable ordinary income in the year of receipt an amount equal to the amount of cash received and the fair market value of any non-restricted shares of Common Stock or other property received.

Value of Benefits

We are unable to determine the amount of benefits that may be received by participants under the 2018 Incentive Plan if the 2018 Incentive Plan is

approved, as grants of awards are discretionary with the Compensation Committee.

Certain Interests of Directors

In considering the recommendation of the Board with respect to the proposal to adopt the 2018 Incentive Plan, shareholders should be aware that our directors have certain interests which may present them with conflicts of interest in connection with such proposal.

Specifically, as discussed above, our directors are eligible to receive awards under the 2018 Incentive

Plan. The Board recognizes that adoption of the 2018 Incentive Plan may benefit our directors and their successors, but believes that approval of the 2018 Incentive Plan will advance our interests and the interests of our shareholders by encouraging directors, employees, consultants and advisors to make significant contributions to our long-term success.

Table of Contents

EXECUTIVE COMPENSATION

TABLES

SUMMARY COMPENSATION TABLE

The following Summary Compensation Table summarizes the total compensation earned by each of the NEOs for the years indicated.

NAME AND POSITION	YEAR	SALARY (\$)	BONUS (\$)(1)	STOCK AWARDS (\$)(2)	NON-EQUITY	ALL OTHER	TOTAL (\$)	
					INCENTIVE PLAN COMPENSATION (\$)(3)	COMPENSATION (\$)		
Fred P. Lampropoulos	2017	1,412,308	400,000	1,838,700	600,000	59,787	(4)(5)	4,310,795
<i>Chair of the Board, Chief</i>	2016	1,267,694		277,020		243,382	(4)(5)	1,788,096
<i>Executive Officer and</i>	2015	1,206,924		286,720	449,999	8,825	(5)(6)	1,952,468
<i>President</i>								
Bernard J. Birkett	2017	514,687	200,000	459,675		219,373	(4)(5)(8)	1,393,735
<i>Chief Financial Officer</i>	2016	511,512	50,000	138,510		347,632	(4)(5)(8)	1,047,654
<i>and Treasurer (7)</i>	2015	296,211	32,000	143,360	48,000	132,915	(8)	652,486
Ronald A. Frost	2017	400,000	200,000	459,675		23,145	(4)(5)	1,082,820
<i>Chief Operating Officer</i>	2016	400,000		110,808		5,963	(5)	516,771
	2015	384,615		114,688	48,000	7,355	(5)(6)	554,658
Joseph C. Wright	2017	473,078		229,838	225,000	15,551	(4)(5)	943,467
<i>President, Merit</i>	2016	450,000		110,808	200,000	5,963	(5)	766,771
<i>International (7)</i>	2015	466,289		57,344	187,217	7,477	(5)(6)	718,327
Brian G. Lloyd	2017	515,385	202,000	459,675		5,963	(5)	1,183,023
<i>Chief Legal Officer,</i>	2016	348,077	52,000	167,523				567,599
<i>Corporate Secretary (7)</i>								

(1) Bonus amounts represent discretionary bonuses not based upon pre-determined performance criteria.

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

(2) Stock Awards reflect the aggregate grant date fair value of the awards granted to the NEOs in the year shown, computed in accordance with FASB ASC Topic 718. Such amounts have been calculated in accordance with current financial statement reporting guidance, using the same assumptions the Company has used for financial statement reporting purposes with respect to our long-term incentive plans. Assumptions used in the calculation of these amounts for 2017, 2016, and 2015 are included in footnotes to our audited consolidated financial statements for the years ended December 31, 2017, 2016, and 2015 (which are included in our Annual Reports on Form 10-K filed with the SEC on March 1, 2018, March 1, 2017, and February 29, 2016, respectively).

(3) Incentive bonuses under our performance-based annual bonus plan based on pre-established performance criteria appear in the Non-Equity Incentive Plan Compensation column. The Compensation Committee's evaluation of our achievement of the performance bonus goals for Mr. Lampropoulos in 2017 indicated that we achieved the goals established for sales, non-GAAP gross margins, GAAP earnings per share and non-GAAP earnings per share. Although we did not achieve the goal for GAAP gross margins, the Compensation Committee noted that a principal factor contributing to that failure was the variability in GAAP gross margin associated with acquisition and integration costs we incurred in connection with multiple acquisition transactions we completed during 2017, including the critical care division of Argon Medical Devices, Inc. and Catheter Connections. The Compensation Committee recognized that those acquisition transactions were undertaken consistent with our growth strategy, were approved by the Board, and reflected the Board's belief that the transactions would increase shareholder value in the long term but would result in significant unbudgeted expenses in the short term. Based upon its assessment of the Board's objective of increasing shareholder value, the Compensation Committee determined to award to Mr. Lampropoulos the full amount of the annual cash bonus objective established for him.

(4) Amounts include vacation benefits paid to the NEOs in cash in lieu of vacation benefits, as follows:

- for the year ended December 31, 2017: Mr. Lampropoulos, \$53,824; Mr. Birkett, \$3,606; Mr. Wright, \$9,588; and Mr. Frost, \$17,183;
and
 - for the year ended December 31, 2016, Mr. Lampropoulos, \$237,420; and Mr. Birkett, \$36,794.
-

Table of Contents

EXECUTIVE COMPENSATION TABLES

(5) Amounts shown also include matching contributions made by the Company for the benefit of the NEOs to our 401(k) Plan in the following amounts:

- for the year ended December 31, 2017: Mr. Lampropoulos, \$5,963; Mr. Birkett, \$5,963; Mr. Wright, \$5,963; Mr. Lloyd, \$5,963; and Mr. Frost, \$5,963;
- for the year ended December 31, 2016: Mr. Lampropoulos, \$5,963; Mr. Birkett, \$2,163; Mr. Wright, \$5,963; and Mr. Frost, \$5,963; and
- for the year ended December 31, 2015: Mr. Lampropoulos, \$5,963; Mr. Wright, \$5,963; and Mr. Frost, \$5,963.

(6) Amounts shown also reflect the incremental travel expenses incurred by the Company for spouses of the following NEOs who attended our off-site President's Award recognition event for the year ended December 31, 2015: Mr. Lampropoulos, \$2,862; Mr. Wright, \$1,514; Mr. Frost, \$1,392.

(7) Mr. Wright, Mr. Birkett and Mr. Lloyd became executive officers of the Company on May 22, 2015, November 4, 2015 and April 1, 2016, respectively. The foregoing table only presents compensation received for periods in which an NEO acted in an executive officer capacity. As such, there is no compensation disclosure provided for Mr. Lloyd for the year ended December 31, 2015.

(8) Pursuant to Mr. Birkett's employment agreement, we paid the following expenses:

- for 2017, \$16,841 for an automobile allowance, \$77,272 for a housing allowance, \$34,668 in educational expenses, \$26,367 for travel expenses, \$41,259 in gross up salary to cover taxes, and various other expenses;
- for 2016, we paid \$16,841 for an automobile allowance, \$55,900 for a housing allowance, \$49,367 in educational expenses, \$35,469 for travel expenses, \$131,426 in gross up salary to cover taxes, and various other expenses; and

- for 2015, we paid \$12,596 for an automobile allowance, \$32,085 in educational expenses, \$38,700 for a housing allowance, and \$28,703 for relocation and travel expenses.

A portion of the amounts reflected in this table for Mr. Birkett was calculated using amounts paid to him in Euros, then converted using the average EUR/USD published foreign exchange rates.

GRANTS OF PLAN-BASED AWARDS

The following table sets forth information concerning plan-based awards to the NEOs during the year ended December 31, 2017.

NAMED EXECUTIVE OFFICER	GRANT DATE	ESTIMATED FUTURE PAYOUTS UNDER NON-EQUITY INCENTIVE PLAN AWARDS (\$) (1)	ALL OTHER OPTION AWARDS: NUMBER OF SECURITIES UNDERLYING OPTIONS GRANTED (#) (2)	EXERCISE PRICE OF OPTION AWARDS (\$/SH) (3)	GRANT DATE FAIR VALUE OF OPTIONS AWARDS (\$)
Fred P. Lampropoulos	N/A 4/14/2017	\$ 600,000	200,000	\$ 28.20	\$1,838,700
Bernard J. Birkett	N/A 4/14/2017	\$	50,000	\$ 28.20	\$ 459,675
Ronald A. Frost	N/A 4/14/2017		50,000	\$ 28.20	\$ 459,675
Joseph C. Wright	N/A 4/14/2017	\$ 225,000	25,000	\$ 28.20	\$ 229,838
Brian G. Lloyd	N/A 4/14/2017	\$	50,000	\$ 28.20	\$ 459,675

(1) Listed amounts reflect target and maximum incentive performance bonuses for 2017. For the year ended December 31, 2017, each of Mr. Lampropoulos and Mr. Wright received the full targeted level of their incentive performance bonus, as

Table of Contents

EXECUTIVE COMPENSATION TABLES

discussed above and as shown in the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table above.

(2) Stock Options vest at the rate of 20.0% per year over five years on the first through the fifth anniversaries of the date of the grant.

(3) The exercise price per share under each stock option is the market closing price on the date of the grant.

OUTSTANDING EQUITY AWARDS AT YEAR END

The following table provides information on the holdings of stock options and other stock awards by the NEOs as of December 31, 2017.

NAMED EXECUTIVE OFFICER	GRANT DATE	NUMBER OF SECURITIES	NUMBER OF SECURITIES	OPTION	OPTION
		UNDERLYING UNEXERCISED	UNDERLYING UNEXERCISED	EXERCISE	EXPIRATION
		OPTIONS EXERCISABLE	OPTIONS UNEXERCISABLE	PRICE (\$)	DATE
Fred P. Lampropoulos	8/11/2011	120,000		13.75	8/11/2018
	10/4/2014	30,000	20,000	12.06	10/4/2021
	2/13/2015	20,000	30,000	17.27	2/13/2022
	1/28/2016	10,000	40,000	16.05	1/28/2023
	4/14/2017		200,000	28.20	4/14/2024
Bernard J. Birkett	8/11/2011	10,000		13.75	8/11/2018
	10/4/2014	6,000	4,000	12.06	10/4/2021
	2/13/2015	10,000	15,000	17.27	2/13/2022
	1/28/2016	5,000	20,000	16.05	1/28/2023
	4/14/2017		50,000	28.20	4/14/2024
Ronald A. Frost	7/31/2013	8,000	2,000	13.14	7/31/2020
	10/4/2014	15,000	10,000	12.06	10/4/2021
	2/13/2015	8,000	12,000	17.27	2/13/2022
	1/28/2016	4,000	16,000	16.05	1/28/2023
	4/14/2017		50,000	28.20	4/14/2024
Joseph C. Wright	8/11/2011	20,000		13.75	8/11/2018
	7/31/2013	8,000	2,000	13.14	7/31/2020
	10/4/2014	15,000	10,000	12.06	10/4/2021
	2/13/2015	4,000	6,000	17.27	2/13/2022
	1/28/2016	4,000	16,000	16.05	1/28/2023
	4/14/2017		25,000	28.20	4/14/2024

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

Brian G. Lloyd	5/2/2016	5,000	20,000	19.72	5/2/2023
	4/14/2017		50,000	28.20	4/14/2024

- (1) Each unvested stock option award vests 20% each year for five years commencing one year from the grant date.

OPTION EXERCISES AND STOCK AWARDS VESTED

No stock options were exercised by the NEOs and no stock awards (within the meaning of Item 402(g) of Regulation S-K under the Securities Act) vested during the year ended December 31, 2017.

NON-QUALIFIED DEFERRED COMPENSATION

Pursuant to the Merit Medical Systems, Inc. Deferred Compensation Plan ([Deferred Compensation Plan](#)), NEOs may elect prior to the beginning of each calendar year to defer the receipt of base salary and bonuses earned for the ensuing calendar year. Amounts deferred are credited to an

unfunded liability account maintained by the Company on behalf of the applicable NEO, which account is deemed invested in and earns a rate of return based upon certain notational, self-directed investment options offered under the Deferred Compensation Plan. The NEOs accounts under the

47 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

EXECUTIVE COMPENSATION TABLES

Deferred Compensation Plan may also be credited with a discretionary employer matching contribution, although no such discretionary contribution was made for 2017 or at any other time since the Deferred Compensation Plan's inception. Participant account balances under the Deferred Compensation Plan are fully-vested and will be paid by the Company to each NEO upon retirement or

separation from employment, or on other specified dates, in a lump sum form or in installments according to a schedule elected in advance by the participant. The following table sets forth certain information regarding the account balances and amounts credited under the Deferred Compensation Plan in 2017 with respect to the NEOs.

NAMED EXECUTIVE OFFICER	EXECUTIVE CONTRIBUTIONS IN LAST FISCAL YEAR (\$)(1)	REGISTRANT CONTRIBUTIONS IN LAST FISCAL YEAR (\$)	AGGREGATE EARNINGS IN LAST FISCAL YEAR (\$)	AGGREGATE WITHDRAWALS / DISTRIBUTIONS (\$)	AGGREGATE BALANCE AT LAST FISCAL YEARS END (\$)
Fred P. Lampropoulos					
Bernard J. Birkett					
Ronald A. Frost			67,238		489,078
Joseph C. Wright	45,577		240,617		1,334,731
Brian G. Lloyd					

(1) These amounts are also reflected in the Summary Compensation Table for the year ended December 31, 2017 as Salary.

The table below shows the funds available for notational investment under the Deferred Compensation Plan and their annual rate of return for the calendar year ended December 31, 2017. These notational investments were generally the same as the mutual fund investment options offered in 2017 under our 401(k) Plan:

NAME OF FUND	RATE OF RETURN
T. Rowe Price Blue Chip Growth	36.17%
American Funds IS International 2	32.14%
Lazard Retirement Emerging Markets Svc	27.82%
MFS VIT II International Value Svc	26.82%
Nationwide VIT International Index II	24.56%
T. Rowe Price Mid Cap Growth II	24.44%
Vanguard VIF Small Company Growth Inv	23.46%
Vanguard VIF Equity Index	21.66%
Vanguard VIF Total Stock Market Index Inv	20.97%
Model Portfolio - Global Growth	18.89%
Model Portfolio - Balanced Growth	16.22%
T. Rowe Price Equity Income II	15.73%
Model Portfolio - Balanced Moderate	13.54%
Goldman Sachs VIT Mid Cap Value Instl	11.07%
Model Portfolio - Balanced Conservative	10.87%
DFA VA US Targeted Value	9.77%
Model Portfolio - Income with Growth	9.15%
PIMCO VIT Total Return Admin	4.91%
Vanguard VIF REIT Index	4.78%
PIMCO VIT Real Return Admin	3.65%
Nationwide VIT Money Market V	0.47%
Van Eck VIP Global Hard Assets Initial	(1.70)%

Table of Contents

EXECUTIVE COMPENSATION TABLES

**POTENTIAL PAYMENTS UPON
TERMINATION OR CHANGE IN CONTROL**

Employment Agreements

In 2016, the Company entered into an Employment Agreement with each of the NEOs, which were amended in 2017. The Employment Agreements (as amended) are described further in the Compensation Discussion and Analysis discussion above.

The Employment Agreements provide payments and benefits in the event of termination of employment under certain circumstances, including in connection with a change in control as follows:

Termination Other Than in Connection with a Change in Control.

If an Executive's employment with the Company is terminated for any reason, voluntarily or involuntarily, with or without Cause (as defined below), other than in Connection with a Change in Control (as defined below), we are obligated to pay the Executive a lump sum cash payment equal to his or her accrued and unpaid base salary and any accrued vacation pay earned but not yet paid through the date of termination, plus a lump sum cash payment equal to the Executive's accrued annual bonus earned for our last fiscal year ending immediately prior to the Executive's date of termination, to the extent not already paid (the sum of such payments hereinafter referred to as the Accrued Obligations). Any additional severance benefit is solely at the discretion of the Company. A termination is deemed to be in Connection with a Change in Control if it occurs on or within two years after the date of a Change in Control or, in the case of involuntary termination without Cause, within six months prior to a Change in Control and in anticipation of the Change in Control.

A Change in Control means:

- the acquisition in one or more integrated transactions by any individual, entity or group of beneficial ownership of more than 30% of the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors;
- certain changes in a majority of the Board and
- consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of our assets

in each case, subject to certain exceptions set forth in the Employment Agreements.

Termination for Good Reason or Without Cause in Connection with a Change in Control

If an NEO's employment with the Company is terminated by the NEO for Good Reason (as defined below) in Connection with a Change in Control or by the Company without Cause in Connection with a Change in Control, the Company is obligated to:

- (a) pay to the NEO any Accrued Obligations to the extent not already paid;

- (b) pay to the NEO a cash severance benefit equal to two times (three times solely in the case of Mr. Lampropoulos) the sum of (i) the NEO's annual base salary then in effect, and (ii) the NEO's average annual bonus for the last three full fiscal years ending prior to the Change in Control;
- (c) continue to provide group health benefits to the NEO and/or NEO's eligible spouse and dependent children for two years (three years solely in the case of Mr. Lampropoulos) after the date of the NEO's termination;
- (d) provide the NEO with certain outplacement services at our expense; and
- (e) pay or provide to the NEO certain other accrued benefits to the extent not already paid or provided.

For purposes of the Employment Agreements, Cause means:

- the willful and continued failure of an NEO to perform his or her duties after a written demand for substantial performance specifically identifying the deficiencies in the Executive's performance has been delivered to the NEO by the Board or, in the case of all NEOs other than the CEO, by the CEO;

49 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

EXECUTIVE COMPENSATION TABLES

- the willful engaging by an NEO in illegal conduct, intentional misconduct or gross negligence which materially and demonstrably injures the Company; or
- violation of written Company policies prohibiting workplace discrimination, sexual harassment, and alcohol or substance abuse.

For purposes of the Employment Agreements, Good Reason means:

- our assignment to the NEO, upon or within two years after a Change in Control, of any duties inconsistent with or that diminishes the NEO's duties, authority or responsibilities under the terms of the NEO's Employment Agreement;
- our failure to comply with certain compensation provisions in the Employment Agreements;
- requiring the NEO to relocate to another office or location upon or within two years of a Change in Control; or
- our failure to require any successor entity to comply with the terms of a respective Employment Agreement.

Termination for Cause or Without Good Reason Following a Change in Control

If the Company terminates an NEO's employment for Cause on or after the date of a Change in Control, the Company must pay to the NEO his or her annual base salary and accrued vacation and must continue to pay and/or provide certain other welfare benefits to the extent not already provided and/or unpaid. If an NEO voluntarily terminates his or her employment without Good Reason upon or following a Change in Control, the Company is obligated to pay the NEO for Accrued Obligations and to provide certain other accrued benefits to the extent not already paid and/or provided.

Termination upon Death or Disability

Upon an NEO's death or disability other than in Connection with a Change in Control, the Company is obligated to pay the NEO (or the NEO's estate) an amount equal to Accrued Obligations plus any additional discretionary severance benefits approved by the Compensation Committee. If an NEO's employment is terminated after the date of a Change in Control by reason of the NEO's death, the Company must also continue to provide certain welfare benefits to the NEO's family for a stated period. If an NEO's employment is terminated after the date of a Change in Control by reason of the NEO's disability, the Company must also continue to provide certain welfare benefits.

Accelerated Stock Option Vesting Upon a Change in Control

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

Under our 2006 Incentive Plan, all otherwise unvested stock options held by NEOs become fully vested upon a change in control as defined below, without regard to whether the NEO terminates employment.

Our 2006 Incentive Plan defines a Change in Control as:

- certain changes in the majority of the Board within a 24-month period;
- the acquisition by any person of 50% or more of the Common Stock or other voting securities;
- consummation of a merger or reorganization of the Company in which neither the Company nor another entity controlled by our shareholders is the surviving entity;
- a sale or other disposition of all or substantially all of our assets to another entity that is not controlled by our shareholders; or
- shareholder approval of a liquidation of the Company.

Table of Contents

EXECUTIVE COMPENSATION TABLES

Amounts Payable upon a Change in Control without Termination of Employment

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The following table shows for each NEO the intrinsic value of his or her otherwise unvested stock options on December 31, 2017 that would have vested had a Change in Control within the meaning of the Employment Agreements occurred on that date,

calculated by multiplying the number of underlying shares by the closing price of Common Stock on the last trading day of 2017 and by then subtracting the applicable option exercise price:

NAMED EXECUTIVE OFFICER	INTRINSIC VALUE OF STOCK OPTIONS (\$)
Fred P. Lampropoulos	5,486,700
Bernard J. Birkett	1,806,510
Ronald A. Frost	1,867,080
Joseph C. Wright	1,336,500
Brian G. Lloyd	1,219,600

The Employment Agreements do not provide for any additional payments to the NEOs merely upon a Change in Control (i.e., absent a termination of employment of the NEOs).

Amounts Payable upon Termination of Employment

Termination without Cause or For Good Reason In Connection with a Change in Control.

The following table shows the amounts that would be payable to each NEO if the Company had undergone a Change in Control within the meaning of the Employment Agreements and the NEO's employment with the Company terminated voluntarily for Good Reason or

involuntarily without Cause, in each case, on December 31, 2017.

Amounts shown in the table do not reflect any accrued vacation and distributions from our 401(k) Plan that are payable to all salaried employees upon termination of employment:

NAMED EXECUTIVE OFFICER	SALARY AND BONUS CONTINUATION (\$)	STOCK OPTION VESTING ACCELERATION (\$) (1)	HEALTH PLAN COVERAGE CONTINUATION (\$) (2)	DEFERRED COMPENSATION PLAN (\$) (3)	TOTAL (\$)
Fred P. Lampropoulos	5,550,000	5,486,700	42,842		11,079,542
Bernard J. Birkett	1,086,667	1,806,510	27,598		2,920,775
Ronald A. Frost	872,000	1,867,080	27,598	489,078	3,255,756
Joseph C. Wright	1,258,145	1,336,500	27,598	1,334,731	3,956,974
Brian G. Lloyd	1,234,667	1,219,600	27,598		2,481,865

(1) Stock Option Vesting Acceleration amounts represent the intrinsic value of the otherwise unvested stock options held by NEOs on December 31, 2017 calculated by multiplying the number of shares underlying such options by the closing price of Company shares on December 29, 2017, the last trading day of 2017 (\$43.20 per share), and by then subtracting the applicable exercise price.

(2) Health Plan Coverage Continuation amounts represent the estimated future cost of providing continuing Company-paid coverage under our group health, disability and life insurance plans for the applicable severance period. The estimated amounts are based upon December 31, 2017 actual premium rates, plus a 10% assumed rate of annual premium cost increases.

(3) Deferred Compensation Plan amounts represent the account balance in each NEO's Deferred Compensation Plan account as of December 31, 2017.

Table of Contents

EXECUTIVE COMPENSATION TABLES

Termination without Cause or For Good Reason (Other Than in Connection with a Change in Control).

The following table shows the amounts that would be payable to each NEO if the NEO's employment had terminated voluntarily for good reason or involuntarily without Cause, other than in connection with a Change in Control, on December 31, 2017 and we had exercised

our discretion to pay severance equal to one year's salary and the annual bonus earned in 2017.

The following amounts are in addition to accrued vacation and distributions from our 401(k) Plan that are payable to all salaried employees upon termination of employment:

NAMED EXECUTIVE OFFICER	DISCRETIONARY SEVERANCE (\$)⁽¹⁾	HEALTH PLAN COVERAGE CONTINUATION (\$)	DEFERRED COMPENSATION PLAN (\$)⁽²⁾	TOTAL (\$)
Fred P. Lampropoulos	2,700,000			2,700,000
Bernard J. Birkett	700,000			700,000
Ronald A. Frost	600,000		489,078	1,089,078
Joseph C. Wright	725,000		1,334,731	2,059,731
Brian G. Lloyd	802,000			802,000

(1) Assumes the Company exercised its discretion to pay severance equal to one year's salary and the 2017 earned bonus.

(2) Deferred Compensation Plan amounts represent the account balance in the NEO's Deferred Compensation Plan account as of December 31, 2017.

Termination on Account of Death, Disability, Involuntary Termination for Cause or Voluntary Resignation without Good Reason.

If, on December 31, 2017, a NEO had died, his employment had been terminated on account of disability, his employment had been terminated for Cause, or he had voluntarily resigned without Good Reason, whether or not in connection with a Change in Control, he would have been entitled to receive only:

- (a) his accrued salary and bonus earned through December 31, 2017;
- (b) accrued but unpaid vacation pay through December 31, 2017;
- (c) distribution of his vested account balance from our 401(k) Plan;
- (d) the payment of insured benefits, if applicable, under our broad-based long-term disability insurance or group term life insurance plans; and
- (e) distribution of his Deferred Compensation Plan account balance.

Table of Contents

EXECUTIVE COMPENSATION TABLES

CEO PAY RATIO

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The following pay ratio and supporting information compares (x) the annual total compensation of our median employee identified by taking into account all of our employees other than our CEO, (including full-time, part-time and employees on leave) and annualizing permanent employees (full-time and part-time) that did not work a full year, (excluding employees on leave under the Family and Medical Leave Act of 1993,

employees called for active military duty, and employees who took an unpaid leave of absence during the period for another reason) (the Median Employee) against (y) the annual total compensation of our CEO (as reported in our Summary Compensation Table), as required by Section 953(b) of the Dodd-Frank Act.

As illustrated in the table below, our 2017 CEO pay ratio was **142 to 1.00**.

COMPENSATION
(\$)

Fred P. Lampropoulos (1)

4,310,795

Median Employee (2)

30,364

(1) Amount represents taxable compensation paid to Mr. Lampropoulos during 2017, plus the fair market value of equity awards granted to Mr. Lampropoulos during 2017. For additional information, see our Summary Compensation Table beginning on page 44.

(2) Amount represents taxable compensation paid to the Median Employee during 2017.

In calculating our 2017 CEO pay ratio, we calculated the annual total compensation (annual taxable compensation) for all employees of the company (other than the CEO) for the year ended December 31, 2017. We believe that annual total compensation is a consistently applied compensation measure and appropriate for determining the median-paid employee.

We used actual annual total compensation (converted, where applicable, to U.S. dollars based on an average annual exchange rate for the year ended December 31, 2017), and did not make any assumptions or adjustments to the amounts determined.

53 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

Audit Matters

AUDIT COMMITTEE REPORT

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Audit Committee provides oversight of our accounting and financial reporting processes, systems of internal accounting and financial controls and the audits of our financial statements. The Audit Committee reviewed with our independent registered public accounting firm and management the financial information included in our audited financial statements. All members of the Audit Committee are independent, as defined in the Marketplace Rules of NASDAQ.

Management is responsible for our internal controls and financial reporting process. Our independent registered public accounting firm is responsible for performing an audit of our financial statements in accordance with generally accepted auditing standards in the United States of America and for expressing an opinion on those financial statements based on its audit. The Audit Committee reviews these processes on behalf of the Board. The Audit Committee has reviewed and discussed with our management and our independent registered public accounting firm the audited financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017. The Audit Committee has also reviewed and discussed management's assessment of the effectiveness of our internal control over financial reporting, and the opinion of our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.

The Audit Committee also has discussed with our independent registered public accounting firm the matters required to be discussed by the Statement

on Auditing Standards No. 61 (Communication with Audit Committee), as amended.

The Audit Committee has received the written disclosures and the letter from our independent registered public accounting firm required by the Statement on Auditing Standards No. 61, as amended, as adopted by the Public Company Accounting Oversight Board, and has discussed with the independent registered public accounting firm its independence. The Audit Committee has also considered whether the provision of the non-audit services described herein under the caption Proposal No. 5 - Ratification of Appointment of Independent Registered Public Accounting Firm is compatible with maintaining the independence of the independent registered public accounting firm.

Based on the review and discussions referred to above, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC.

AUDIT COMMITTEE
Nolan E. Karras (Chair)
Franklin J. Miller, M.D.
Thomas J. Gunderson

PROPOSAL NO. 5 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Subject to shareholder ratification, the Audit Committee has recommended, and the Board has appointed, the firm of Deloitte & Touche LLP, ([Deloitte](#)) independent registered public accountants, to audit the financial statements of the Company for the year ending December 31, 2018.

Board Recommendation

**The Board unanimously recommends a vote
FOR this proposal**

Deloitte has acted as the independent public accounting firm for the Company since 1988. The Board anticipates that representatives of Deloitte will be present at the Annual Meeting, will have an opportunity to make a statement if they so

Table of Contents

AUDIT MATTERS

desire, and will be available to respond to appropriate questions.

Fees Paid to Our Independent Certified Public Accounting Firm

The following table presents aggregate fees for audits of our consolidated financial statements and fees billed for other services rendered by Deloitte for the years ended December 31, 2017 and 2016.

	2017 (\$)	2016 (\$)
Audit Fees (1)	993,286	835,920
Audit-Related Fees (2)	81,083	27,527
Tax Fees (3)	313,513	326,041
All Other Fees (4)	151,443	131,000
Total	1,539,325	1,320,488

(1) **Audit Fees:** The aggregate fees billed by Deloitte, the member firms of Deloitte Touche Tohmatsu, and their respective affiliates (collectively, the Deloitte Firms) for professional services rendered for the audits and reviews of our financial statements filed with the SEC on Forms 10-K, 10-Q, 8-K and S-3. Audit fees for 2017 and 2016 also include fees for the audit of management's assessment of the effectiveness of internal control over financial reporting and the audit of the effectiveness of our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002.

(2) **Audit-Related Fees:** The aggregate fees billed by the Deloitte Firms for all audit-related services, including an audit of our employee benefit plan and service related to our public offering of Common Stock.

(3) **Tax Fees:** The aggregate fees billed by the Deloitte Firms for tax compliance, tax advice and tax planning.

(4) **All Other Fees:** The aggregate fees billed by the Deloitte Firms related to due diligence services rendered during 2017 and 2016, respectively.

Pre-Approval Policies and Procedures

The Audit Committee ensures that the Company engages its independent registered public accounting firm to provide only audit and non-audit services that are compatible with maintaining the independence of its public accountants. The Audit Committee approves or pre-approves all services provided by our public accountants. Permitted services include audit and audit-related services, tax and other non-audit related services. Certain services are identified as restricted. Restricted services are those services that may not be provided by our external public accountants, whether identified in statute or determined in our opinion to be

incompatible with the role of an independent auditor. All fees identified in the preceding table were approved by the Audit Committee. During 2017, the Audit Committee reviewed all non-audit services provided by our independent registered public accounting firm and concluded that the provision of such non-audit services was compatible with maintaining the independence of the external public accountants.

55 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

Stock Ownership and Trading

PRINCIPAL HOLDERS OF VOTING SECURITIES

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The following table sets forth information as of March 28, 2018, with respect to the beneficial ownership of shares of Common Stock by each person known by the Company to be the beneficial owner of more than 5% of the Common Stock, by each director, by each director nominee, by each NEO and by all directors and executive officers as a group.

For each individual and group included in the table below, percentage ownership is calculated by dividing

the number of shares beneficially owned by such person or group by the sum of the 50,325,883 shares of Common Stock outstanding as of March 28, 2018, plus the number of shares of Common Stock that such person or group had the right to acquire on or within 60 days after March 28, 2018.

Unless otherwise noted, each person named has sole voting and investment power with respect to the shares indicated.

PRINCIPAL SHAREHOLDERS	NUMBER OF SHARES	PERCENTAGE OF OUTSTANDING COMMON STOCK
Blackrock, Inc. (1)	6,197,350	12.3%
The Vanguard Group, Inc. (1)	4,527,791	9.0%
Officers, Directors and Nominees		
Fred P. Lampropoulos (2) (3)	1,417,015	2.80%
Kent W. Stanger (2) (3)	549,757	1.09%
Michael E. Stillabower, M.D. (3)	145,668	*
Franklin J. Miller, M.D. (3)	129,437	*
Nolan E. Karras (3)	77,000	*
Ronald A. Frost	69,198	*
Joseph C. Wright (3)	62,000	*
Bernard J. Birkett (2) (3)	52,075	*
A. Scott Anderson (3)	30,400	*
Brian G. Lloyd (2) (3)	20,059	*
F. Ann Millner, Ed.D.	13,644	*
David M. Liu, M.D.	9,200	*
Thomas J. Gunderson (3)	5,000	*
Total Officers, Directors and Nominees	2,640,453	5.16%

* Represents a holding of less than 1.0%

(1) Based upon the most recent Schedules 13G available on the SEC's website as of March 28, 2018. Number of shares listed represents aggregate amount of shares of Common Stock beneficially owned by each reporting person as indicated in the applicable Schedule 13G report.

(2) The computations above include the following share amounts that are held in our 401(k) Plan on behalf of participants as of March 28, 2018:

- Mr. Lampropoulos, 94,239 shares
- Mr. Stanger, 42,228 shares
- Mr. Frost, 16,198 shares
- All executive officers and directors as a group, 152,665 shares.

Table of Contents

STOCK OWNERSHIP AND TRADING

(3) The computations above include the following share amounts that are subject to options exercisable within 60 days after March 28, 2018, none of which had been exercised as of such date:

- Mr. Lampropoulos, 240,000 shares
- Mr. Stanger, 62,750 shares
- Dr. Stillabower, 110,000 shares
- Dr. Miller, 100,000 shares
- Mr. Karras, 53,000 shares
- Mr. Frost, 53,000 shares
- Mr. Wright, 62,000 shares
- Mr. Birkett, 51,000 shares
- Mr. Anderson, 24,000 shares
- Mr. Lloyd, 20,000 shares
- Dr. Millner, 10,000 shares
- Dr. Liu, 9,200 shares
- Mr. Gunderson, 5,000 shares
- All executive officers and directors as a group, 876,950 shares

Section 16(a) Beneficial Ownership Reporting Compliance

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

Section 16(a) of the Exchange Act requires that our executive officers, directors and persons who beneficially own more than ten percent of the Common Stock must file with the Securities and Exchange Commission ([Commission](#)) initial reports of ownership and reports of changes in beneficial ownership of the Common Stock and other securities that are derivative of the Common Stock.

Executive officers, directors and ten percent or greater shareholders are required by Commission regulations to furnish us with copies of all Section 16(a) reports they file.

Based solely upon a review of the copies of those forms and written representations from our executive officers and directors, we believe that all Section 16(a) reports required to be filed by our officers and directors during the year ended December 31, 2017 were filed timely.

57 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

Other Proxy Information

INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

On behalf of the Company, the Board is soliciting your proxy to vote at our 2018 Annual Meeting of Shareholders (or at any adjournment of the meeting) (the [Annual Meeting](#)). This Proxy Statement includes information you need to know to vote at the Annual Meeting.

Date, Time and Place of the Annual Meeting

Date: May 24, 2018

Time: 3:00 p.m. (local time)

Place: Merit Medical Headquarters

1600 West Merit Parkway

South Jordan, UT 84095

This Proxy Statement, the Notice of Annual Meeting of Shareholders and the accompanying form of proxy are first being mailed or made available to our shareholders on or about April 13, 2018.

We will bear all costs and expenses relating to the solicitation of proxies, including the costs of preparing, printing and mailing to shareholders this Proxy Statement and accompanying materials, as well as the expense of making this Proxy Statement and accompanying materials available on the Internet (although shareholders must bear any costs associated with their

Internet access). In addition to the solicitation of proxies by use of the mail and the Internet, our directors, officers, and employees, without receiving additional compensation, may solicit proxies personally or by telephone, electronic mail or facsimile. Arrangements will be made with brokerage firms and other custodians, nominees and fiduciaries for the forwarding of solicitation materials to the beneficial owners of the shares of Common Stock held by those persons, and we will reimburse those brokerage firms, custodians, nominees and fiduciaries for reasonable out-of-pocket expenses incurred by them in connection therewith.

The Board has fixed the close of business on March 28, 2018 as the record date for determination of shareholders entitled to receive notice of and to vote at the Annual Meeting (the [Record Date](#)). As of the Record Date, there were issued and outstanding 50,325,883 shares of Common Stock. The holders of record of the shares of Common Stock on the Record Date entitled to be voted at the Annual Meeting are entitled to cast one vote per share on each matter submitted to a vote at the Annual Meeting.

Method for Electronic Viewing and Printing of the Proxy Materials

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

The Record Date for the Annual Meeting is March 28, 2018. Shareholders of record on the Record Date will be entitled to notice and to vote, in person or by proxy, at the Annual Meeting and any adjournments or postponements thereof.

SEC rules allow companies to furnish their proxy materials over the Internet. As a result, the Company is mailing to most of its shareholders a Notice of Internet Availability of Proxy Materials (the [Notice](#)) instead of a paper copy of this Proxy Statement and our 2017 Annual Report to Shareholders. The Notice contains instructions on how to access those documents over the Internet. The Notice also contains instructions on how to request a paper copy of our proxy materials, including this Proxy Statement, the 2017 Annual Report to Shareholders and a form of proxy card or voting instruction card. All

shareholders who do not receive a Notice will receive a paper copy of the proxy materials by mail. We believe this process will allow us to provide shareholders with the information they need in a more efficient manner, while reducing the environmental impact and lowering the costs of printing and distributing these proxy materials.

All shareholders may choose to access our proxy materials on the website (www.proxyvote.com) or may request to receive a printed set of our proxy materials. This Proxy Statement contains information regarding the proposals to be considered at the Annual Meeting, and shareholders are encouraged to read it in its entirety.

Table of Contents

OTHER PROXY INFORMATION

Proxies

Shares of Common Stock that are entitled to be voted at the Annual Meeting and are represented by properly executed proxies will be voted in accordance with the instructions on those proxies.

If no instructions are indicated, shares on a properly executed proxy will be voted:

- **FOR** the election of each of the three director nominees identified in this Proxy Statement;
- **FOR** the amendment to increase the maximum Board size (from 9 to 11);
- **FOR** the non-binding resolution to approve the compensation of our named executive officers;
- **FOR** approval of our new 2018 Incentive Plan; and
- **FOR** the ratification of the appointment of Deloitte to serve as our independent registered public accounting firm for the year ending December 31, 2018.

In respect of any other matters that may properly come before the Annual Meeting, shares represented by properly executed proxies may be voted at the discretion of the proxy holder. The Board is not currently aware of any other matters to be presented at the Annual Meeting.

Revocation of Proxies

A shareholder who has executed and returned a proxy may revoke it at any time prior to its exercise at the Annual Meeting by executing and returning a proxy bearing a later date by mail, by voting via the Internet, by filing with Brian G. Lloyd, our Corporate Secretary, at the address set forth above, a written notice of revocation bearing a later date than the proxy being revoked, or by voting the Common Stock covered thereby in person at the Annual Meeting. In order to revoke a proxy executed

with respect to shares held in street name, the shareholder must contact the appropriate broker or nominee.

Broker Non-Votes

Shares of Common Stock that are held in street name, which means shares of Common Stock held of record by a trustee or in an account at a brokerage firm, bank, dealer, or other similar organization (collectively, brokerage firms), may be voted, even if the beneficial holder does not provide the brokerage firm with voting instructions. Brokerage firms have the authority under applicable securities rules to cast votes on certain routine matters, even if they do not receive instructions from their customers. However, the ratification of our independent registered accounting firm is considered the only routine matter for which brokerage firms may vote un-instructed shares. The election of directors, the amendment to increase the maximum Board size, the advisory vote to approve named executive officer compensation, and the approval of our 2018 Incentive Plan are not considered routine matters under current securities rules. When a proposal is not a routine matter and the brokerage firm has not received voting instructions from

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

the beneficial owner of the shares with respect to that proposal, the brokerage firm cannot vote the shares on that proposal. This is called a broker non-vote.

As all of the proposals described in this Proxy Statement, other than the proposal to ratify our independent registered accounting firm, are considered to be non-routine matters, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares.

59 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

OTHER PROXY INFORMATION

Vote Required

A majority of the issued and outstanding shares of Common Stock entitled to vote, properly represented in person or by proxy, is required for a quorum at the Annual Meeting. Abstentions and broker non-votes will be counted as represented for the purpose of determining the presence or absence of a quorum. Under the Utah Revised Business Corporation Act, once a quorum is established, shareholder approval with respect to a particular proposal is generally obtained when the votes cast in favor of the proposal exceed the votes cast against the proposal.

Holders of shares of Common Stock are entitled to one vote at the Annual Meeting for each share of Common Stock held of record on the Record Date. The vote required for each of the proposals described in this Proxy Statement is as follows:

PROPOSAL 1: In the election of directors, shareholders will not be allowed to cumulate their votes. Each director-nominee who receives a majority of the votes cast with respect to his or her election will be elected as a director of the Company.

PROPOSAL 2: The proposal to amend our Articles to increase our maximum board size from nine to 11 directors requires a vote in favor from holders of at least two-thirds of our outstanding shares of Common Stock.

PROPOSAL 3: The advisory vote on executive compensation is non-binding. Nevertheless, we will record the number of votes cast in favor of and against the proposal and will report the voting results.

PROPOSAL 4: Approval of the proposal to adopt the 2018 Incentive Plan requires that the votes cast in favor of the proposal must exceed the votes cast against the proposal.

PROPOSAL 5: The proposal to ratify the appointment of Deloitte to serve as our independent registered public accounting firm for the year ending December 31, 2018 requires that the votes cast in favor of the proposal must exceed the votes cast against the proposal.

Abstentions and broker non-votes will not affect the outcome of the first, third and fourth proposals. However, because the second proposal requires the affirmative approval of holders of at least two-thirds of our outstanding shares of common stock, abstentions and broker non-votes will be effectively act as votes against that proposal and will affect the outcome of that proposal. Finally, abstentions will not affect the outcome of the fifth proposal, but because that proposal is considered a routine matter, brokerage firms may vote un-instructed shares for or against the proposal.

No Dissenters - Rights of Appraisal

There are no rights of appraisal or similar dissenters' rights with respect to any matter to be acted upon pursuant to this Proxy Statement.

Table of Contents

OTHER PROXY INFORMATION

Methods of Voting

The method of voting by proxy differs for shares registered directly in a shareholder's name, considered the shareholder of record, and shares held in street name, which means shares held of record by a trustee or in an account at a brokerage firm, bank, dealer, or other similar organization.

Holders of Record

If the shareholder holds shares as a record holder, the shareholder may vote the shares by proxy on www.proxyvote.com, by means of the telephone (at 1-800-690-6903), by mail (by requesting a printed copy of this Proxy Statement and then voting by mail), or by attending the Annual Meeting and voting in person. Each method is discussed further below:

- **Voting by Mail.** If a shareholder chooses to vote by mail, simply mark the Proxy and complete, sign, date and mail it in the postage-paid envelope provided. The Proxy must be completed, signed and dated by the shareholder or the shareholder's authorized representative.
- **Voting by Telephone.** Shareholders of record can vote by phone by following the instructions on the Proxy or by calling toll-free at 1-800-690-6903. Voice prompts will instruct shareholders to vote their shares and confirm that their vote has been properly recorded.
- **Voting over the Internet.** Registered shareholders can vote on the Internet by accessing the Internet at www.proxyvote.com. As with telephone voting, shareholders can confirm that their votes have been properly recorded. We provide Internet proxy voting to allow shareholders to vote their shares online, with procedures designed to ensure the authenticity and correctness of proxy vote instructions. However, please be aware that shareholders must bear any costs associated with their Internet access, such as usage charges from Internet access providers and telephone companies.
- **Voting in Person at the Annual Meeting.** If a shareholder plans to attend the Annual Meeting and vote in person, we will provide a ballot at the

Annual Meeting. Shareholders of record have the right to vote in person at the Annual Meeting.

If a shareholder requests a printed copy of this Proxy Statement, a proxy card (the **Proxy**) will also be mailed to the shareholder. If a shareholder votes his, her or its proxy by telephone, the Internet or by returning the Proxy to us before the Annual Meeting, the individuals designated in the Proxy will vote as the Proxy directs. If a shareholder votes by telephone or over the Internet, the shareholder does not need to return the Proxy.

Telephone and Internet voting facilities for shareholders will be available 24 hours a day, and will close at 11:59 p.m., Eastern Time, on May 23, 2018.

Holders in Street Name

If a shareholder holds shares of our common stock in street name, the shareholder must either instruct his, her or its broker or nominee as to how to vote such shares or obtain a proxy card, executed by the broker or nominee, to be able to vote at the Annual Meeting.

Shareholders who hold shares in street name can generally vote by telephone when they receive their materials by mail from his, her or its broker or nominee using the toll-free phone number located on the Proxy.

A large number of banks and brokerage firms are participating in the Broadridge Investor Communications Solutions, Inc. ([Broadridge](#)) online program. This program provides eligible shareholders the opportunity to vote via the internet or by telephone. If a shareholder's bank or brokerage firm is participating in Broadridge's program, the voting form will provide instructions.

If a shareholder holds shares in street name and the shareholder wishes to vote at the Annual Meeting, the shareholder will need to bring to the Annual Meeting a legal proxy from the broker or other nominee authorizing the shareholder to vote those shares.

Shareholders receiving multiple Notices, or whose shares are registered in more than one name or are registered in different accounts, should follow the voting instructions on each Notice to ensure that all of their shares are voted.

61 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

OTHER PROXY INFORMATION

Additional Information and Additional Copies of Proxy Materials

We will provide without charge to any person from whom a proxy is solicited by the Board, upon the written request of that person, a copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including the financial statements and schedules thereto (as well as exhibits thereto, if specifically requested).

We will generally deliver one copy of this Proxy Statement to each address where multiple record holders of our Common Stock reside, unless we have received instructions to the contrary. We will promptly deliver another copy of this Proxy Statement to any holder of its Common Stock living at a shared address

where we have delivered only one Proxy Statement.

Written requests for additional information or additional Proxy Statements should be directed to:

Merit Medical Systems, Inc.

Attn: Brian G. Lloyd

1600 West Merit Parkway

South Jordan, Utah 84095

OTHER MATTERS

As of the date of this Proxy Statement, the Board knows of no matters to be presented for action at the Annual Meeting other than those matters described in the preceding pages. If, however, any further business

should properly come before the Annual Meeting, the persons named as proxies in the accompanying form will vote on that business in accordance with their best judgment.

SHAREHOLDER PROPOSALS
FOR ANNUAL MEETING 2019

If any shareholder intends to present a proposal to be considered for inclusion in our proxy materials in connection with our 2019 Annual Meeting of Shareholders, the proposal must be in proper form (per SEC Regulation 14A, Rule 14a-8 - Shareholder Proposals) and received by our Corporate Secretary no later than December 14, 2018. Nominations of persons for election as directors must be made consistent with the provisions of our Second Amended and Restated Bylaws, including the requirement that the shareholder provide timely notice of the nomination in proper written form to our Corporate Secretary.

In accordance with the procedures set forth in our Second Amended and Restated Bylaws, shareholders who wish to submit a proposal for consideration at our

2019 Annual Meeting of Shareholders, including a nomination for director, but who do not wish to submit a proposal for inclusion in our proxy statement, must deliver notice of the proposal to our Corporate Secretary at our principal executive offices no earlier than December 25, 2018 and no later than January 24, 2019. Such proposals must contain all information required by our Second Amended and Restated Bylaws. If the month and day of the next annual meeting is advanced or delayed by more than 30 calendar days from the month and day of the annual meeting to which this Proxy Statement relates, we will inform our shareholders of the change in a timely manner, as well as any change in the date by which proposals of shareholders must be received.

Table of Contents

OTHER PROXY INFORMATION

NON-GAAP FINANCIAL MEASURES

Although our financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and the majority of the financial measures described in this Proxy Statement and our Annual Report for the year ended December 31, 2017 are calculated in accordance with GAAP, the Board and Compensation Committee use certain non-GAAP financial measures referred to in this Proxy Statement in order to assess year-over-year performance. We believe that such non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of our ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures referred to in this Proxy Statement include:

- non-GAAP gross margin; and
- non-GAAP earnings per share.

NON-GAAP GROSS MARGIN

Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets, inventory mark-up related to acquisitions and severance.

Our management team uses these and other non-GAAP financial measures to evaluate our profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of its operating segments, and to measure and allocate financial resources internally. Our Board and Compensation Committee use these non-GAAP financial measures to assess the performance of certain of our NEOs. Neither our management nor our Board and Compensation Committee consider any such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP.

NON-GAAP EARNINGS PER SHARE

Non-GAAP earnings per share is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

You should consider non-GAAP measures used in this Proxy Statement in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect our financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. We believe it is useful to exclude such items in the calculation of non-GAAP earnings per share and non-GAAP gross margin (in each case, as further illustrated in the reconciliation table below) because such amounts in any specific period may not directly correlate to the underlying performance of our business operations and can vary significantly between periods as a result of factors such as new acquisitions, non-cash expenses related to amortization of

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

previously acquired tangible and intangible assets, unusual compensation expenses or expenses resulting from litigation, governmental proceedings or changes in tax regulations. We may incur similar types of expenses in the future, and the non-GAAP information included in this Proxy Statement should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this Proxy Statement may not be comparable with similarly titled measures of other companies. We urge readers to review the reconciliations of our non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business or results of operations.

Tables reconciling our 2017 non-GAAP gross margin and non-GAAP earnings per share to equivalent GAAP measures are included below:

63 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

OTHER PROXY INFORMATION

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME**(UNAUDITED, IN THOUSANDS EXCEPT PER SHARE AMOUNTS)**

	Three Months Ended, December 31, 2017				Per Share Impact
	Pre-Tax	Tax Impact (a)	After-Tax		
GAAP net income	\$ 11,280	\$ (4,474)	\$ 6,806	\$	0.13
<i>Non-GAAP adjustments:</i>					
Cost of Sales					
Amortization of intangibles	5,490	(1,848)	3,642		0.07
Inventory mark-up related to acquisitions	279	(39)	240		
Operating Expenses					
Severance	446	(171)	275		0.01
Acquisition-related (b)	1,593	(532)	1,061		0.02
Fair value adjustment to contingent consideration (c)	(338)	131	(207)		
Long-term asset impairment charge (d)	93	(36)	57		
Intangible asset impairment charge (e)	809		809		0.02
Amortization of intangibles	1,908	(703)	1,205		0.02
Special legal expense (f)	2,001	(779)	1,222		0.02
Other (Income) Expense					
Gain on bargain purchase (g)	(243)		(243)		
Amortization of long-term debt issuance costs	171	(67)	104		
Tax expense related to tax reform (h)		1,855	1,855		0.04
Non-GAAP net income	\$ 23,489	\$ (6,663)	\$ 16,826	\$	0.33
Diluted shares					51,722

Table of Contents

OTHER PROXY INFORMATION

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME**(UNAUDITED, IN THOUSANDS EXCEPT PER SHARE AMOUNTS)**

	Year Ended, December 31, 2017			Per Share Impact
	Pre-Tax	Tax Impact (a)	After-Tax	
GAAP net income	\$ 35,881	\$ (8,358)	\$ 27,523	\$ 0.55
<i>Non-GAAP adjustments:</i>				
Cost of Sales				
Amortization of intangibles	20,705	(7,550)	13,155	0.26
Inventory mark-up related to acquisitions	3,400	(1,253)	2,147	0.04
Operating expenses				
Severance	2,185	(847)	1,338	0.03
Acquisition-related (b)	6,648	(2,048)	4,600	0.09
Fair value adjustment to contingent consideration (c)	(298)	116	(182)	
Long-term asset impairment charge (d)	179	(70)	109	
Acquired in-process research and development	12,136	(97)	12,039	0.24
Intangible asset impairment charge (e)	809		809	0.02
Amortization of intangibles	6,111	(2,324)	3,787	0.07
Special legal expense (f)	12,616	(4,908)	7,708	0.15
Other (Income) Expense				
Gain on bargain purchase (g)	(11,039)		(11,039)	(0.22)
Amortization of long-term debt issuance costs	685	(267)	418	0.01
Tax expense related to tax reform (h)		1,855	1,855	0.04
Non-GAAP net income	\$ 90,018	\$ (25,751)	\$ 64,267	\$ 1.28
Diluted shares				50,101

- a. Reflects the tax effect associated with pre-tax income and the non-GAAP adjustments
- b. Represents costs related to acquisitions
- c. Represents changes in the fair value of contingent consideration liabilities and contingent receivables as a result of acquisitions
- d. Represents abandoned patents

Edgar Filing: MERIT MEDICAL SYSTEMS INC - Form PRER14A

- e. Represents impairment charges of certain intangible assets
- f. Costs incurred in responding to an inquiry from the U.S. Department of Justice
- g. Represents the gain on bargain purchase realized from the acquisition of the critical care division of Argon Medical Devices, Inc.
- h. Tax expense recorded as our estimated one-time net income tax charge resulting from the enactment of the Tax Cuts and Jobs Act

65 **2018 PROXY STATEMENT** | www.merit.com

Table of Contents

OTHER PROXY INFORMATION

**RECONCILIATION OF REPORTED GROSS MARGIN
TO NON-GAAP GROSS MARGIN (NON-GAAP)
(UNAUDITED, AS A PERCENTAGE OF REPORTED REVENUE)**

	Twelve months ended December 31, 2017
Reported Gross Margin	44.8%
<i>Add back impact of:</i>	
Amortization of intangibles	2.8%
Inventory mark-up related to acquisitions	0.5%
Severance	%
Non-GAAP Gross Margin	48.1%

Exhibits

EXHIBIT 1 Second Amended and Restated Articles of Incorporation of Merit Medical Systems, Inc.

EXHIBIT 2 Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan

